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Pseudorables (Aujeszky's Disease) has been recognized since 
the beginning of the century as a highly contagious disease of 
1 2 3 4 5 
swine which has a world-wide distribution. » » » » 
Susceptibility to pseudorables virus (PRV) Infection varies 
according to species, individual, age, Immune status, and route 
of infection. 
The spread of PRV among swine herds has forced the animal 
industry to implement vaccination programs in an attempt to reduce 
economic losses which are present in the form of deaths, abortions 
and stillbirths. There are two general types of commercially 
available federally licensed PRV vaccine in the United States, 
the inactivated and the modified live. Research has been conducted 
on the effects of challenge with virulent strains of PRV in swine 
after immunization with both of these vaccines. 
In this work, the effects of administering virulent PRV to 
animals with declining immunity after vaccination with each type 
of vaccine were evaluated by the following parameters: a) clinical 
signs, b) gross lesions, c) microscopic lesions, d) levels of 
cellular immunity, e) levels of humoral Immunity and f) presence of 
viral antigens. 
2 
More knowledge of the effects of PRV in hogs with declining 
immunity is essential for better implementation of an effective 
pseudorabies control program. 
3 
OBJECTIVES 
The objectives of this study were; 
a) to determine the effects of declining immunity on lesion 
development and clinical disease in swine after exposure to 
virulent PRV; 
b) to determine if cellular immunity is useful in predicting 
response to challenge and potential carrier animals; 
c) to determine age resistance factors in vaccinated and non-
vaccinated swine after challenge with a virulent PRV; and 
d) to determine the effects of humoral and cellular immunity 
on the isolation of virus. 
4 
DISSERTATION FOBMAT 
This dissertation is presented in alternate format including 
two manuscripts to be submitted to the American Journal of Veterinary 
Research. The manuscripts are presented in the format required by 
the American Journal of Veterinary Research except footnote notations 
which comply with the Iowa State University Graduate College Thesis 
Manual. References cited in each manuscript are Included and are in 
compliance with the American Journal of Veterinary Research. The 
manuscripts are preceded by a general introduction, objectives of 
the investigation and a literature review. General discussion 
and conclusions from the investigation follow the second manuscript. 
Additional literature cited refers to citations from the 
general Introduction and discussion and is listed in a format 
consistent with the one used in the manuscripts. 
The Ph.D. candidate, Roberto Alva-Valdés, was the main 
Investigator for each of the studies and is the senior author for 
each of the manuscripts. Co-authors work and assistance from 




In 1902, Aladar Aujeszky, a Hungarian veterinarian, reported 
for the first time in a published manuscript a fatal disease which 
occurred naturally in cattle, dogs and cats and which was transmissible 
18 6 
to laboratory animals. A few years later in 1931, Shope concluded 
that a similar disease occurring in Iowa cattle and known as "mad 
itch" was the same condition as Aujeszky's disease. 
19 20 
Pursuing his investigation, in 1934 and 1935, Shope ' 
demonstrated that swine were affected by the same agent which caused 
"mad itch" in cattle and called it pseudorables (PR). In the same 
work, he noted that the disease spread readily through the swine herd 
and that, if cattle were pastured in the same lot, transmission 
took place through abrasions in the skin. He noted, however, that 
the disease was not transmitted from cow to cow. 
20 
In 1934, Shope demonstrated antibodies against PRV in swine 
21 
from the mldwestern United States. In 1953, Edison et al. 
isolated the virus from infected dogs in the states of Louisiana, 
Alabama, Georgia and Florida (USA). 
22 
In an interesting paper published by Hanson, previous 
evidence is analyzed which indicates that PR might have been 
present In the United States long before its historical recognition 
by Dr. Aujeszky in 1902. However, the fact that "mad itch" was the 
same condition as PR was to be proven some years later. 
6 
Since those early days, outbreaks of PR have been reported in 
most swine producing areas of the world. 
In 1932, Bang^ reported the first outbreak of PR in Denmark. In 
subsequent years, the occurrence of PR. in swine was indicated by 
23 4 
the following workers: Bendinger (1936, Russia), Vlanello 
(1942, Italy), Lamont and Shanks^^ (1947, Northern Ireland), 
^ c 2k 
Ghenev and Stoyanov (1958, Bulgaria) , tïaêld (1961, Yugoslavia) , 
27 28 29 
Johnston et al. (1961, England), Becker (1961), Germany), Bartosz 
(1962, Poland), Hipollto et al.^° (1962, Brazil), Lin et al.^^ (1972, 
China and Taiwan). 
The clinical picture seen in PR is dependent on factors such as 
5 32 
species, age, immune status of the host and strain of PRV. ' 
Four major forms of clinical PR are described: (1) a central nervous 
system (CNS) form, (2) a form Involving both the CNS and the respiratory 
tract, (3) a genital form and (4) a disseminated form In which every 
major organ in the body may be Involved. It is generally accepted 
that in most outbreaks of PR the CNS is affected. The damage 
produced in the brain is reflected in the live animal as incoordina-
2 8 32 33 
tion, opisthotonos and convulsions. ' ' ' 
Other clinical manifestations of PR included prostration, 
reluctance to move, anorexia, pain, sneezing, mucopurulent exudate 
in the nostrils, vomiting, muscle tremors, paddling, salivation, 
2 7 28 IS 
ataxia, convulsions, coma and death. *>>>*> Pruritus 
IX 36 
in swine has been reported ' ; however, it is not a constat feature 
37 
as it Is in cattle. 
7 
Age resistance to PRV Infection is widely accepted, and 
5 38 
mortality is most common in animals less than 3 weeks of age. ' 
Mortality in older pigs is not a common finding, however it does 
32 38 
occur. * Abortions, stillbirth and mummifications are common 
11 33 39 in pregnant sows. ' * Vaginal discharges and conjunctivitis 
have been observed in pregnant gilts after challenge with PRV.^^ 
40 
A recent paper by Larsen et al, described no significant 
difference among the semen properties of infected and non-infected 
boars when no systemic disease accompanied the infection. 
I 41 
Mare and Kluge raised the question of whether PRV and 
myoclonia congenita in baby pigs were associated; however, no 
final conclusion was reached. 
42 
Posterior paralysis was reported by Olander et al. in swine 
challenged intramuscularly with PRV. 
Different degrees of blindness in natural outbreaks of PR in 
43 
swine have been reported. 
Gross Lesions 
The location, distribution and severity of lesions in swine 
infected with PRV are dependent on age, dose, route of infection, 
virus strain and immune status.^'^'^'^^'^^'^^'^^ 
Different strains of PRV possess different affinities for a 
particular tissue. The most commonly affected tissues are those 
of the central nervous system, lungs, tonsils, turbinates, liver, 
spleen and regional lymph nodes. Less frequently affected tissues 
8 
Include placenta, adrenal gland, eye, oral mucosa, heart, kidney, 
intestine and te=ticle.''-»-28.".44,45,«,47 
Central nervous system 
In the nervous form of PR no gross lesions have been reported 
with the exception of meningeal congestion In cerebrum and 
cerebellum.11'42'43'48 
9 Comer reported the presence of petechial hemmorrhages on 
the ependymal lining of the olfactory bulb In PRV Infected swine. 
Respiratory tract 
The lesions In the respiratory form of PR are seen In the upper 
and lower respiratory tract. The nasal turbinates may have a 
variety of lesions ranging from slight hyperemia and congestion 
to suppurative rhinitis with focal areas of mucosal ulcera-
tlon.7'*'*'ll'14'49'50 
Lesions In the epiglottis and trachea are not a common 
finding; however, Kluge and Marè^^ reported the presence of a diffuse 
flbrlnopurulent exudate on turbinates, epiglottis, trachea and 
bronchi of pregnant gilts Infected intranasally with a virulent 
strain of PRV. The mucosa of those structures was hyperemlc, 
hemorrhagic and ulcerated. Congestion and edema were seen In 
retropharyngeal, mandibular and tracheobronchial lymph nodes. 
Purulent pharyngitis has been an occasional finding.Similar 
8 11 
changes have been noted in the oral mucosa, tongue and esophagus. * 
9 
The gross lesions In the lungs are characterized by congestion, 
dark red consolidation and large amounts of exudate In the Intertl-
tlum, bronchioles and bronchi. 
Different workers have reported the presence of multifocal 
9 45 44 
yellow-white 2-3 mm foci in the pneumonic areas. Hurst 
reported an increase in pleural and pericardial fluid with 
petechial hemorrhages in the serosa of infected animals. Lung 
lesions are distributed in the apical, cardiac and diaphragmatic 
lobes. 
Other organs 
Relatively constant gross lesions in young animals have been 
seen with some PRV strains particularly in the liver, spleen and 
tonsils. The lesions are characterized by moderate congestion and 
multifocal whitish to yellowish non-raised 2-3 mm foci. 
The same type of lesions has been observed with less frequency 
in the heart, intestine, testicle, adrenal gland, oral mucosa, and 
9 45 42 
tongue. ' Olander et al. reported petechial hemorrhages 
in the renal papillae and peripheral lymph nodes of PRV infected 
swine. 
Microscopic Lesions 
The microscopic changes observed in swine Infected with 
PRV are subject to the same variables that affect the clinical 
signs and gross lesions. Those variables are age of the host. 
P 
10 
6 7 8 10 11 
Immune status, virus strain, dose and route of Infection. *' * * * 
12,13,14,53 
Nervous system 
The lesions seen in the central nervous system (CNS) have been 
described as a non-suppuratlve meningoencephalitis. A constant finding 
is a perivascular infiltration (cuffing) of lymphocytes, macrophages, 
eosinophils, and occasional neutrophils. Such cells have the tendency 
of forming cuffs of 1 to 3 layers in thickness. 
Varying degrees of vasculitis and endothelial damage have been 
reported In different parts of the CNS. The brain parenchyma has mild 
to severe mononuclear perivascular Infiltration with focal areas of 
necrosis, malacia, demyellneation, edema, microglial nodules, and 
olidendrogllal proliferation. Infiltration of reactive astrocytes, 
gitter cells, and a few neutrophils has been observed scattered 
throughout the brain parenchyma. 
Neuronal degeneration characterized by shrunken hyperchromatlc 
nuclei and chromatolysls is a constant feature. 
Kluge and Marê^^ noted a marked pyknosis and karyorrhesis of the 
perivascular inflammatory cells in the brain. 
The presence of different types and sizes of eosinophilic 
Intranuclear inclusion bodies has been a matter of discussion by 
several workers.Basophilic Intranuclear inclusion 
bodies were observed in Intranasally Infected swine, while no 
inclusions were noted when the aerosol route of infection was 
11 
53 
utilized. The type of inclusions seen by these workers was 
described as being Cowdry's type A, and were characterized as single, 
large, discrete, spherical bodies producing marglnatlon of the 
nuclear chromatin. The workers also indicated that some inclusions 
completely filled the nuclei and were homogeneous to granular in 
appearance. The presence of small bodies around the nucleus was 
also described. The inclusion bodies were observed In the cerebral 
cortex and sub-cortical white matter and were rare in areas where 
dense microglial nodules were present. Lesions in the trigeminal 
and spinal ganglia have been reported and are similar to those 
42 described for the brain parenchyma. The predilection sites for 
the lesions in the CNS were reported to be the cerebral and cerebellar 
cortices. The less affected area» Involved the brain stem mainly 
48 
in the dorsal half around tha cerebral aqueduct and ventricles. 
Respiratory tract 
The microscopic lesions produced in the upper and lower 
50 
respiratory tract were reported in detail" by Baskervllle et al. , 
57 58 
and Baskervllle. * The lesions in the nasal turbinates were 
characterized by focal areas of necrosis involving the epithelium 
and lamina propria. The necrotic foci measured 0.1 to 2 mm in 
size. Eosinophilic Intranuclear Inclusion bodies were reported 
in a few epithelial cells. The mucosa had extensive Infiltration 
of lymphocytes, macrophages, plasma cells, and a few neutrophils. 
Edema and thickening of the mucosa were also observed. 
12 
The lesions In the lungs were characterized by multifocal 
areas of necrosis in the alveoli, bronchioles and bronchi, A 
mixed inflammatory reaction composed of lymphocytes, macrophages, 
plasma cells, eosinophils, mast cells, and a few neutrophils 
was reported in the alveoli, bronchlolar epithelium and bronchial 
epithelium. Eosinophilic intranuclear Inclusion bodies were seen 
in bronchlolar epithelial cells, in cells of the septa and in 
alveolar pneumocytes. Severe necrotic vasculitis was a common 
finding. Congestion, hemorrhages and moderate amounts of fibrin 
were present in the alveoli. The distribution of the lesions varied 
from small focal areas to diffusely scattered zones throughout 
58 57 
the lobules. Baskerville noted that bronchioles were more 
often affected than bronchi. Moderate amounts of desquamated 
epithelium were present in the bronchioles. In contrast to the 
36 
above report, Becker reported the presence of only a mild 
interstitial pneumonia without necrotic changes. 
Bronchial squamous metaplasia was reported in the repair stages, 
59 
Baskerville demonstrated by the use of electron microscopy that 
PRV infected all types of cells in the lungs. 
Other organs 
Microscopic lesions have been reported In the tonsils, spleen, 
liver, heart, intestine, testicle, esophagus, adrenal gland, oral 
mucosa, tongue, eye, local lymph nodes, placenta, kidney, trachea, 
and bone marrow.28,43,44,49 
13 
The liver, tonsils, and spleen are the most consistently affected. 
Lesions are not commonly seen in other organs. The lesions are 
characterized by multifocal areas of coagulative necrosis with an 
inflammatory cell infiltration composed of lymphocytes, macrophages, 
eosinophils, plasma cells and a few neutrophils. Basophilic 
intranuclear inclusion bodies are frequently seen within and at 
the periphery of the necrotic foci. The types of inclusions are 
similar as those described for the CNS. Different degrees of 
vasculitis and large amounts of eosinophilic homogeneous and 
fibrillar proteinaceous material have been observed in small 
v e s s e l s . I n  t h e  t o n s i l s ,  t h e  l e s i o n s  i n v o l v e  
62 
the squamous epithelium of the crypts and surrounding tissue. 
Placental lesions are characterized by focal coagulative necrosis 
of the chorionic fossae with large homogeneous eosinophilic to 
basophilic intranuclear inclusion bodies in trophoblasts and 
mesenchymal cells. A mild inflammatory reaction has also been 
63 
noted in the nesenchyma. 
Pseudorabies Vaccines 
The use of different types of PR vaccines has been reported 
extensively in the literature. Modified live, inactivated, and 
even unattenuated live vaccines have been used. The different 
methods of inactlvatlon and modification are described else­
where. 64,65,66,67,68,69,70,71,72,73,74,75,76,77 
14 
Reports of the effectiveness of either modified live pseudorables 
virus (MLPRV) or Inactivated pseudorables virus (IPRV) vaccines have 
a great range of variation. 
Modified live vaccines 
According to some workers, the advantages of MLPRV vaccines 
are the induction of a good humoral response and the need for only 
78 79 80 81 
a single dose for proper immunization. ' * ' The main disadvantages 
are the excretion of attenuated virus by vaccinated animals after 
administration of some vaccines and the possibility of vaccine 
virus reverting to virulence.Some workers found no 
excretion of attenuated virus by hogs vaccinated with a MLPRV 
vaccine which was prepared from a Bucharest strain of PRV.^^*^® 
Other authors reported that some types of MLPRV vaccines have failed 
to induce a detectable humoral antibody response and failed to 
protect against infection. However, these vaccines were effective 
in reducing mortality in young swine challenged with virulent 
70 71 82 83 
PRV. ' * ' The resistance to challenge in animals vaccinated 
with a MLPRV vaccine was reported to last 6 to 12 months. 
The multiplication and distribution of PRV in pigs immunized 
with a K strain of PRV grown in vero cells was demonstrated by 
84 
McFerran and Dow. No excretion of vaccine virus was detected. 
This modified live PRV vaccine was isolated from lymph nodes, CNS 
85 
and occasionally from adrenal glands. 
15 
The challenge of pigs with PRV after vaccination resulted in 
81 
shedding of the challenge virus. The use of MLPRV vaccines has 
proven on occasions to be more effective in preventing mortality 
in young pigs than inactivated vaccines. However, neither one has 
prevented the development of clinical signs nor the excretion of 
80 
virulent virus. 
No adverse effect was demonstrated in pregnant sows after 
86 
the use of either MLPRV or IPRV vaccines. 
87 
Leeuw and Tiessink indicated that the use of an IPRV vaccine 
did not offer complete protection when swine were exposed to PRV 
a few months later, and that one vaccination with the MLPRV vaccine 
gave better protection than two applications of the inactivated 
88 
type. Zuffa and Salaj indicated that a single vaccination with 
MLPRV or IPRV vaccine resulted in protection from clinical illness 
but not from Infection. The formation of neutralizing antibodies 
was detected after immunization of pigs with a MLPRV vaccine given 
89 by subcutaneous, intramuscular or intratracheal route. 
Inactivated vaccines 
The greatest advantage of the IPRV vaccine is the lack of risk 
of vaccine virus being excreted.One of the disadvantages, 
however, is that inactivated vaccines are more difficult to 
check for purity because adjuvant may preclude the use of cell 
80 
culture. Some types of IPRV vaccines have been effective in 
reducing mortality and development of clinical signs in challenged 
16 
s w i n e . W i t t m a n n  e t  a l . ^ ^  d e m o n s t r a t e d  t h a t  p i g s  i m m u n i z e d  
with an IPRV vaccine as well as non-immunized pigs both contained 
the same amounts of PRV in the serum after intranasal exposure. 
This occurred in spite of the presence of high antibody titers in 
the vaccinated group. They concluded that the multiplication of 
PRV in pigs immunized with an IPRV vaccine is reduced but not suppressed 
and that the distribution of the virus by the lymphatics and blood 
stream is not prevented by vaccination. The vaccinated animals 
In this experiment did not develop clinical signs. 
In some studies, higher humoral antibody titers of longer duration 
have been observed in pigs which received IPRV vaccine, than those 
80 88 92 
that received MLPRV vaccine. ' * 
91 
In a report by Cecil and King, eighteen weeks after immunization 
with an IPRV vaccine only 50% of the animals had detectable antibody 
titers. However, when the animals were challenged at this time 
no mortality was observed. In the same report, the authors indicated 
that 80% of a group of sows seroconverted following vaccination 
91 
and that good immunity was transferred to their suckling pigs. 
Wittmann et al.^^ demonstrated that multiplication and distribu­
tion of PRV in selected tissues of pigs challenged after immunization 
with an IPRV vaccine were the same as in non-vaccinated exposed 
animals in spite of the presence of neutralizing antibodies. However, 
the virus titers in the organs were lower during the first 7 days 




Robert Koch, in 1890 described for the first time the skin 
reaction occurring in tuberculous humans and guinea pigs following 
the subcutaneous administration of tuberculin. The reaction was 
characterized by a focal area of induration and swelling. This 
was the first indication that delayed-type hypersensitivity (DTH) 
occurs in animals and humans. 
Cell-mediated immunity (CMl) is evaluated by the effects of 
94 
specific antigens on specific lymphocytes ^  vitro. Generally, 
thymus derived lymphocytes (T cells) are responsible for this 
phenomenon; however, cells derived from stem cells of the bone 
95 96 97 
marrow (B cells) may play an important role in this reaction. ' ' 
Between 1960 and 1979, researchers demonstrated that if previously 
sensitized lymphocytes obtained from animals with a DTH were 
incubated jja vitro with specific antigens, these lymphocytes released 
98 99 100 
soluble mediators. * * These mediators called lymphokines have 
been reported to be the product of both T and B cells. 
The following lymphokines have been described: migration 
102 103 inhibitory factor, macrophage specific chemotactic factor, 
lymphocyte permeability factor,aggregation factors, 
proliferative-lnhibitory factor,macrophage activator factor, 
cytophilic antibodies,and interferon. 
Vladimarson^'^^ reported that after lymphoklne production has 
taken place, T cells undergo blastogenesls with further differentiation 
into memory cells. Ware and Granger^^^ stated that thymus derived 
18 
lymphocytes reacted to foreign histocompatibility antigens by undergoing 
antigen Induced clonal selection, proliferation and differentiation. 
Ill Oppenheim demonstrated the transformation of lymphocytes to lympho-
blasts in immune animals. 
112 
Blanden made the observation that T lymphocytes alone could 
provide protection against viral infection. 
Immune T cells can activate macrophages, thus inducing a delayed 
hypersensitivity response, secrete lymphokines and interferon, 
interact with macrophages and B cells for the stimulation of a specific 
antibody response and act as a direct cytotoxic factor for the cells 
113 
infected with a virus. 
Other method of measuring cell-mediated immune response is by the 
use of the intradermal skin test. Several workers have reported 
that PR vaccinated pigs have a DTH reaction when exposed intracutaneously 
to PRV antigen.116,117 
118 
Rottinghaus et al. found that the intradermal skin test was 
inferior in detecting cell-mediated Immune response in pigs infected 
with PRV when compared to the lymphocyte transformation test vitro. 
Other authors have reported about 50% agreement when the intradermal 
skin test and the serum neutralization test were compared as diagnostic 
119 
methods for PR in swine. 
Three common techniques are used to measure the effects of 
specific antigens on the T cell population: lymphocyte blast transforma­
tion, leukocyte migration inhibition, and leukocyte adherence 
inhibition.*^ 
19 
The blast transformation test measures the proliferative response 
120 121 
of previously sensitized T cells to a specific antigen. ' The 
sensitized T cells are characterized In light microscopy by an 
Increased basophilia and ultrastructurally by cytoplasm containing 
122 
large amounts of rlbosomes and almost no endoplasmic reticulum. 
Lymphocyte transformation in vitro 
The lymphocyte transformation assay vitro by the use of 
microtiter techniques has been used in the study of cell-mediated 
immunity in man,123'124,125 mouse,cattle/^^'^^® plg.^^* 
h o r s e , d o g , ^ ^ ^  c a t , ^ ^ ^  s h e e p , g u i n e a  p i g . ^ ^ S  r a b b i t ,  
137 
and birds. 
The lymphocyte transformation test measures the proliferative 
response of sensitized T cells to a specific antigen. Some B cells 
120 121 
may also be stimulated in the process. ' 
3 
The degree of incorporation of H thymidine into nuclear 
deoxyribonucleic acid (DNA) Indicates the extent of the lymphocyte 
138 
prollf eratlon. 
Besides specific antigens such as viruses, bacteria, and fungi, 
nonspecific plant mitogens possess the capability of inducing a 
blastogenlc transformation in B and T lymphocytes. 
The reaction to the different plant mitogens can be specific 
142 for either cell type or can Involve both the T and B populations. 
T cells respond to phytohemagglutlnln (PHÂ) but not to pockweed 
mitogen (PWM), B cells, on the other hand, respond to PWM but 
20 
not to PHA. It is to be noted that some degree of stimulation may 
be seen in either type of cells when using the different types of 
143 144 
mitogens; however, it is not of great significance. * 
The detection of cell-mediated immunity in herpes virus infection 
by the use of the lymphocyte transformation tests has been performed 
with lymphocytes of the peripheral blood and cells from lymphoid 
123 128 135 tissue and spleen of different species of animals and man. > > > 
145,146 
123 
Steele et al. working with human lymphocytes demonstrated a 
blastogenic response in people infected with Herpes simplex virus. 
Other herpes viruses of animals have been shown to induce lymphocytic 
blastogenesis ^  vitro. 
Different workers demonstrated a lymphocyte transformation 
response in cattle infected with the herpes virus of infectious 
bovine rhinotracheitis.^28,147,148,149 
Lymphocyte transformation in PRV challenged swine 
The use of lymphocyte transformation as a method of detecting 
the cell-mediated Immune response is swine infected with PRV 
^ ^ ^ . 118,150,151 has been recently reported. 
In 1976, Nittmann et al. demonstrated lymphocyte transforma­
tion ^  vitro in lymphocytes from the circulating blood, spleen, 
thymus and lymph nodes of PRV infected swine. The first response 
took place 4 days after infection and was demonstrated for 35 days in 
lymphocytes from the lymph nodes and spleen. Lymphocytes from blood 
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and thymus reacted with less frequency, while bone marrow lymphocytes 
showed no response. Serum neutralization titers were first detected 
at day 7. The authors concluded that cell-mediated immunity influences 
the early stage of infection because antibody titers were absent or not 
detected in the first days after challenge. 
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In 1976, Smith reported a lymphoprollferatlve response 
and antibody titers on day 14 and 21 after intradermal inocula­
tion of PKV antigen into nonimmune swine. 
118 
In 1978, Rottinghaus et al. demonstrated a lymphocyte 
proliferating response in PRV infected pigs. These workers used 
lymphocytes from the peripheral blood and observed that the earliest 
response to the antigen was on day 6 after challenge and that the 
greatest response was on days 13 and 14. The lymphocyte response 
continued for 70 days after infection. Circulating antibodies were 
detected for the first time at 8 days after exposure, peaked on 
day 11 and stayed at a high level until the experiment was completed 
70 days later. 
Lymphocyte transformation has been Induced in lymphocytes of 
pigs vaccinated with modified live and Inactivated pseudorables 
99 1 SI 1 SI 151 
vaccines. ' ' In 1979, Olrschot demonstrated that sensitized 
lymphocytes appeared in the peripheral blood of vaccinated swine between 
days 7 and 14 after immunization with a modified live PRV vaccine. The 
lymphoprollferatlve response in this experiment was still present 
174 days after vaccination. This response was detected in lymphocytes 
from the spleen and peripheral blood. 
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Humoral Antibody Determination 
Different techniques have been used for the detection of 
circulating antibodies in PRV infected swine. Some of the tests 
include: microtitration serum neutralization test (SN),^^^ micro-
immunodiffusion test,^^^*^^^ macroimmunodiffusion test,^^^ indirect 
158 
solid-phase microradioimmunoassay test, countercurrentimmuno-
electrophoresis,^^^ indirect immunoperoxidase method,enzyme-linked 
immunosorbent assay, (ELISA),^^^ direct immunoperoxidase test,^^^ and 
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complement fixation test. 
It is generally accepted that the microtiter serum neutralization 
test is one of the most sensitive tests available for the detection of 
PRV antibodies in swine sera. However, good evidence has been collected 
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SUMMARY 
The effects of vaccination against pseudorabies virus infection 
were studied in 93 castrated male pigs. The pigs were divided into 
7 groups and challenged with a virulent strain of pseudorabies 
virus at 1, 3, 5, 8, 10, 12 and 14 months after vaccination. 
Federally licensed modified live and inactivated pseudorabies 
virus vaccines were used as the immunizing agents. The protection 
provided was evaluated by the comparison of clinical signs, gross 
lesions and microscopic lesions among vaccinated and non-vaccinated 
pigs after challenge with an Iowa strain of pseudorabies virus. 
Histopathologic changes were described for different areas 
of the central nervous system and other tissues. 
Neither the modified live nor the inactivated pseudorabies 
virus vaccines prevented clinical signs or microscopic lesions in 
pigs after challenge. However, both vaccines diminished the severity 
of clinical signs and microscopic lesions for a period up to 8 
months after vaccination. 
Protection against clinical signs and microscopic lesions was 
absent 10 months after vaccination. 
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INTRODUCTION 
Pseudorabies (Âujeszky's Disease) has been recognized since 
the beginning of the century as a highly contagious infectious 
12 3 
disease of swine. ' ' 
The susceptibility of animals to pseudorabies virus (PRV) is 
dependent on different factors such as species, individual, age, 
immune status, virus strain and route of infection.^ 
The clinical signs, gross lesions and histopathologic changes 
observed in young swine infected with PKV may affect the nervous 
and respiratory system or may involve every major organ in the body 
9 10 11 12 
when a disseminated form is present. ' ' * 
The use of modified live and inactivated pseudorabies virus 
vaccines in swine has been reported by several workers. 
In one study, the utilization of a modified live PRV (MLPRV) vaccine 
proved to be more effective than inactivated PKV vaccines in preventing 
mortality in young swine. In other studies some types of inactivated 
PRV (IPRV) vaccine were effective in reducing mortality and the 
development of clinical signs in swine challenged with a virulent 
strain of PRV.^^*^^*^^ The multiplication and distribution of 
PKV in pigs immunized with MLPRV and IPRV vaccines and then exposed 
to a virulent strain of PRV has been reported to be the same as in 
non-vaccinated pigs.^^'^^ In other studies, however, evidence is 
presented in which pigs vaccinated with MLPRV vaccines excreted smaller 
amounts of virus for a reduced number of days after challenge than 
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the non-vaccinated challenged controls. In addition, the replication 
of viral particles and lesions were restricted to limited areas of 
20 21 
the brain. ' The dissemination of challenge virus in vaccinated 
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animals has been demonstrated to be reduced. 
A difference in distribution of brain lesions has been observed 
in vaccinated animals. Swine vaccinated with the MLPRV vaccine and 
then challenged with a virulent strain of PRV had lesions primarily 
in the post-cerebrum to midbrain region, while those animals which 
received the IPRV vaccine before challenge had lesions throughout the 
. , 16 brain. 
In another study, the microscopic lesions observed in pigs 
challenged with a virulent strain of PRV after vaccination with a 
MLPRV vaccine were restricted to the medulla, rhinencephalon and 
adjacent ventro-lateral gyri and consisted of a few thin perivascular 
20 
cuffs with microglial foci in the gray matter. 
The objectives of this study were to determine the long term 
effects of declining immunity on clinical signs and lesion development 
in groups of pigs vaccinated with a commercially available MLPRV 
or IPRV vaccine and challenged later with a virulent PRV. 
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MATERIALS AND METHODS 
Procedures 
Animals and housing 
Ninety-three seven-week-old castrated male crossbred (Yorkshire 
X Hampshire X Duroc) pigs were purchased from a commercial source. 
The source herd was free of serologic evidence of pseudorabies, 
transmissible gastroenteritis, leptospirosis and clinical evidence 
of atrophic rhinitis. Upon arrival, the pigs were allowed to remain 
undisturbed for an 8 day acclimation period. All the pigs were 
tested for pseudorabies antibody using the microtltration serum 
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neutralization test. 
Housing consisted of total confinement for the first three months 
and open front buildings with concrete floored pens, self feeders 
and automatic drinkers for the remainder of the experiment. A commercial 
balanced diet was fed ^  libitum for the first 5 months. After the 
fifth month the feed was limited to 1.5 kg per pig per day until the 
animals were killed. 
Experimental design 
Treatment groups based on time of challenge Included groups 
I, II, III, IV, V, VI, VII. Groups I through IV contained 12 
animals each, while groups V, VI, and VII were composed of 15 
pigs each. 
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Each group consisted of 4 pigs vaccinated with MLPRV vaccine, 
4 pigs vaccinated with IPRV and 4 pigs inoculated with a placebo 
injection (PI). Three pigs were added to each of the V, VI and VII 
groups. These animals were regarded as vaccinated but not challenged 
controls. The three pigs consisted of 1 vaccinated with the MLPRV 
vaccine, 1 vaccinated with the IPRV vaccine and 1 inoculated with the 
PI solution. 
Vaccines and vaccination 
The animals were initially grouped so that pigs were randomly 
allotted to three vaccine categories. They were vaccinated 
simultaneously at nine weeks of age including the pigs which 
received the PI injections. 
The 31 pigs which received MLPRV^ vaccine were penned 
separately from the 31 which received IPRV^ vaccine and those 
which received placebo injections to prevent any chance exposure 
to MLPRV. Both vaccines were administered according to manufacturer^' 
recommendations. The MLPRV vaccine was administered once by the 
intramuscular route (2 ml), while 2 doses of IPRV vaccine were 
given subcutaneously 14 days apart. The control placebo injection 
consisted of a single intramuscular injection of 2 ml of sterile 
distilled water. 
Borden Laboratories Inc., Lincoln, Nebraska 68501, U.S.A. 
^Salsbury Laboratories, Charles City, Iowa 50616, U.S.A. 
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The pigs in the three vaccine categories commingled evenly in 
three large pens containing 31 pigs each until 90 days after 
immunization. 
Virus propagation 
A field isolate of an Iowa strain of PRV at the 9th and 
10th tissue culture passage containing 1.6 x 10^ and 5 x 10^ plaque 
forming units, respectively, was inoculated into a 48 hour old 
monolayer of pig kidney cells (PK 15). The cells were contained 
2 in 150 cm tissue culture flasks. The virus was allowed to adsorb 
to the cells for 60 minutes at 37"C in a 5% COg atmosphere. Following 
adsorption, the supernatant was removed and minimum essential 
medium (HEM) containing 2% fetal calf serum was added to the flasks. 
The flasks were reincubated until 90% of the cells developed 
cytopathic effect (CPE). The flasks containing the 9th passage 
virus were frozen and thawed twice at -70°C and 37°C, respectively. 
The flasks containing the 10th passage virus were frozen and thawed 
once under the same procedure. The cells and supernatant were 
then centrifuged at 1500 xg for 20 minutes in a refrigerated 
centrifuge. The supernatant was used as the challenge virus. 
Exposure 
Each group of 12 pigs was divided at random in two subgroups. 
Each sub-group consisted of 2 pigs vaccinated with the MLPRV 
vaccine, 2 pigs vaccinated with the IPRV vaccine and 2 pigs 
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injected with the PI'solution. Each subgroup was housed in an 
isolation unit and exposed to the virulent PRV. 
Groups I and II were challenged with 2 ml of the Iowa strain 
of PRV at the 10th tissue culture passage containing 1.6 x 10^ 
plaque forming units per ml. Groups number III, IV, V, VI, and 
VII received the same strain of virus at the 11th passage containing 
5 X 10^ plaque forming units per ml. Each animal received 2 ml of 
liquid inoculum in each nostril. The virus was administered deeply 
into the nasal cavity with the aid of a sterile canula and syringe. 
Table 1 indicates the exposure schedule of each group following 
vaccination. 
Table 1. Challenge schedule following vaccination 
Group I II III IV V VI VII 
Challenge with PRV, 1 
months after 
vaccination 
3 5 8 10 12 14 
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Following challenge, the animals were observed for clinical 
signs. The rectal temperature was taken twice daily in the 
morning and afternoon. After rectal temperature peaked and began 
to decline, half of the animals were killed (2 pigs vaccinated with 
the MLPRV vaccine, 2 pigs vaccinated with the IPRV vaccine and 2 
pigs injected with the PI solution). The remaining 6 pigs in 
each group were killed 60 days after challenge. Body weight was 
recorded immediately after electrocution. A necropsy was performed 
and gross lesions were recorded. Small sections of tissue were 
fixed in 10% buffered formaldehyde solution. The tissues were 
processed by routine paraffin technique and sections stained with 
hematoxylin and eosln. 
Hlstotechniques 
The tissues taken for histopathologic examination were: 
a) central nervous system (trigeminal ganglia, hypophysis, 
cerebral cortex at the level of the olfactory bulb and optic 
chlasma, mid brain between rostral and caudal colliculi, thalamus, 
pons, cerebellum, medulla, cervical spinal cord taken at the level 
of the sixth and seven cervical vertebra, thoracic spinal cord 
taken at the level of the seven thoracic vertebra, lumbar spinal 
cord taken at the level of the fourth lumbar vertebra and sacral 
spinal cord taken at the level of the fourth sacral vertebra); 
b) respiratory system (nasal turbinates, trachea, tracheobronchial 
lymph nodes, apical, cardiac, diaphragmatic and Intermediate 
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lobes of the lungs); c) digestive system (parotid salivary gland, 
esophagus, liver, stomach, duodenum, jejunum, ileum, colon and 
pancreas); d) haemopoietic system (thymus, jejunal lymph nodes, 
mandibular lymph nodes, tonsils and spleen); e) urinary system 
(kidneys and urinary bladder); f) cardiovascular system (heart). 
Utilizing the techniques described by Halvorsen^^ 1 mm cubes 
of brain and tonsils were placed in 2.5% glutaraldehyde in 0.1 
M Sorensen's buffer and processed for electron microscopy. Selected 
sections from the hematoxylin and eosin stained sections were also 




The gross lesions were recorded during necropsy and were scored 
with the numerals 0 or 1 according to the absence or presence of 
lesions in the following tissues: a) turbinates (congestion and 
purulent exudate); b) lungs (congestion, consolidation and pneumonia); 
c) tonsils (necrosis). 
The microscopic evaluations of lesions in the central nervous 
system (CNS) were scored according to the severity and distribution 
of the following changes: congestion, edema, malacia, necrosis, 
microglial nodules, perivascular cuffing, neuronophagla, reactive 
astrocytes, gitter cells, swollen axons, satellitosis and inclusion 
bodies. 
For the analysis of the microscopic lesions in tissues outside 
the CNS the following changes were scored: necrosis, edema. 
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perivascular cuffing, presence of lymphocytes, macrophages, plasma 
cells, eosinophils, neutrophils and fibrin, vasculitis, hemorrhages 
and inclusion bodies. 
A scale of 1 to 5 was assigned to each of the lesions. In the 
CNS, these numerical values represented both severity and distribution 
of individual lesions. Number 1 indicates no lesions while number 
2, 3, 4, or 5 represented progressively increasing lesion severity. 
The individual lesion scores were added and an average lesion score 
was obtained for each tissue. These values were used for the 
statistical analysis. 
The same system was utilized to evalute the lesions in other 
tissues with the only difference that the numerals utilized were 1 
through 4. The youngest PI treated and most severely affected pig 
in the first group was considered the most susceptible animal and 
was utilized as a positive control. 
Before the microscopic evaluation of each animal, the positive 
control slides were reviewed to increase scoring repeatability. 
In order to increase objectivity, all the slides were evaluated 
by one person without knowing the status of the animal being 
examined. The data was analyzed by using the analysis of variance 
procedure. Table 2 summarizes the experimental design. 
Table 2. Experimental design 
Original groups 
II III IV V VI VII 
Challenge with PRV 
(months after vaccination) 1 3 5 8 10 12 14 
number of animals 12 12 12 12 15 15 15 
Each 
f 
contained the folio 
4 pigs vaccinated with the MLPRV vaccine 5 pigs vaccinated with the MLPRV vaccine 
4 pigs vaccinated with the IPRV vaccine 5 pigs vaccinated with the IPRV vaccine 
4 pigs injected with the PI solution 5 pigs injected with the PI 
i I 
Necropsy of 6 pigs seven days after challenge with the virus 
T 
2 pigs vaccinated with the MLPRV vaccine 
2 pigs vaccinated with the IPRV vaccine 
2 pigs injected with the PI solution 
t 
Necropsy of the remaining 6 pigs 
60 days after challenge 
2 pigs vaccinated with the MLPRV vaccine 
2 pigs vaccinated with the IPRV vaccine 
2 pigs injected with the PI solution 
Collection and 
t 
Necropsy of the remaining 9 pigs 
60 days after challenge 
2 pigs vaccinated with the MLPRV 
2 pigs vaccinated with the IPRV 
2 pigs injected with the PI 
1 pig vaccinated with the MLPRV not exposed 
1 pig vaccinated with the IPRV not exposed 
1 pig injected with the PI not exposed 
evaluation of data 
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RESULTS 
Body temperature (BT) began to rise In all the pigs 24 hours 
after challenge (AC). The temperatures reached their maximum and 
began to decline at different Intervals according to group and 
Immune status of the animal. 
In general, BT began to decline between days 4 and 6 AC. The 
pigs which received the MLPRV vaccine had an overall significantly 
lower mean BT AC followed by the IPRV vaccinated and PI Injected, 
respectively (Table 3, Figure 1). 
Pigs In groups I, III and IV had significantly higher (P < .05) BT AC 
than groups II, V, VI and VII (Table 4, Figures 2 and 3). 
Thirty-six hours AC all the animals were anorexic, prostrate 
and reluctant to move. Feces were usually very firm. Severe 
sneezing and purulent exudate flowing from the nostrils were noted 
In some Individuals at 48 hours AC. 
Nlnety-slx hours AC some of the vaccinated and non-vaccinated 
pigs began vomiting; at this point, prostration became prominent 
in the pigs that received the PI solution. The? nostrils, 
ears and midlines of the prostrate animals were deep red-purple. 
The pigs that were immunized with either the IPRV or the MLPRV 
vaccines began recovering between 5 and 7 days AC, while those 
animals Injected with the PI solution remained sick for an 
additional 6 to 7 days. Only one pig died at 48 hrs after challenged; the 
animal was vaccinated with an IPRV vaccine and belonged to challenge group 
IV. 
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All the animals from challenge groups I, III, IV, V, VI and VII 
had clinical signs of illness by day number 3 AC. The PI injected 
pigs were the most severely affected while no difference in clinical 
illness was noted between the pigs that received the MLPRV or the 
IPRV vaccines. 
Purulent exudate flowing from the noses was noted in the 
following animals: a) all the PI injected pigs in challenge 
groups I, III and IV; b) one pig vaccinated with the MLPRV vaccine 
and one vaccinated with the IPRV vaccine in challenge group II; 
c) all the pigs in challenge group V; d) two pigs immunized with 
the IPRV vaccine and two immunized with the MLPRV vaccine in challenge 
group VI. None of the animals in challenge group VII had purulent 
exudate in the nostrils. 
By day number 7 AC two PI injected pigs from challenge group 
I had CNS signs characterized by incoordination, loss of balance, 
tilting of the head and backward movements. None of the pigs 
in challenge group II had evidence of clinical illness. 
The animals which received the PI Injections in challenge 
groups I, III and IV had a more severe clinical illness than those 
which received the MLPRV and the IPRV vaccines. No detectable 
difference in clinical illness was noted between the pigs which 
received the two types of vaccine (MLPRV or IPRV), 
The animals in challenge groups V, VI and VII were equally 
affected regardless of the type of vaccine received. 
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Gross Lesions 
Only 18 out of 93 pigs used in this experiment had gross 
lesions. All the animals with lesions were killed at 7 days AC, 
while no lesions were observed in the pigs killed at 60 days AC. 
Lesions were confined to the respiratory tract and were 
characterized by one or a combination of the following changes: 
a) congestion of turbinates with purulent exudate in the nasal 
cavity; b) pneumonia with congestion, consolidation and white 
areas measuring 2-5 mm; c) tonsillar necrosis; d) enlargement, 
congestion and edema of regional lymph nodes. 
In 14 animals, the lesions were confined to the nasal 
turbinates. All the PI Injected pigs in challenge groups I, III 
and IV had a highly significant difference (P < ,0001) in the severity 
of lesion scores In the turbinates when compared to the IPRV and 
MLPRV vaccinated pigs. 
Only one pig vaccinated with the MLPRV vaccine and one 
vaccinated with the IPRV vaccine in challenge group II had 
purulent exudate on the turbinates. 
There was no significant difference in turbinate lesions 
among pigs In challenge group V. 
Two pigs vaccinated with the MLPRV vaccine and two vaccinated 
with the IPRV vaccine in challenge group VI had a purulent exudate 
on the turbinates, while one pig Injected with the PI solution 
and 1 vaccinated with the MLPRV vaccine in challenge group VII had 
purulent exudate on the turbinates (Figure 4). 
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Only 6 pigs had pneumonic lesions. Three of them were PI injected 
pigs from challenge groups I, II and IV. The other three were 
vaccinated with the IPRV vaccine and belonged to challenge groups 
V (one) and VI (two). 
Lung lesions were predominantly in the apical, cardiac 
and intermediate lobes (Figure 5). Gross lesions were not 
a significant feature among the different treatment groups (PI 
Injected, IPRV and MLPRV vaccinated). 
Microscopic Lesions 
The microscopic lesions observed were of the same type in 
all the vaccinated and non-vaccinated pigs AC. However, a difference 
in severity was noted between the pigs which received the PI 
solution and those which received the MLPRV or the IPRV vaccines. 
The analysis of data was done by comparing the lesion scores of 
the PI Injected pigs with the lesion scores of the vaccinated pigs 
and the lesion scores among vaccinated animals. 
The microscopic lesions were observed in the following tissues: 
a) central nervous system (all sections taken); b) respiratory system 
(nasal turbinates, tracheobronchial lymph nodes, and apical and 
Intermediate lobes of the lungs; and c) haemopoletlc system 
(mandibular lymph nodes and tonsils). 
Central nervous system 
In the animals killed at 7 days AC, the lesions were characterized 
by a lympho-histlocytic-eoslnophilic meningoencephalitis with focal 
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areas of edema, demeylinatlon, necrosis and malacla. The aforementioned 
foci contained large numbers of gltter cells, lymphocytes, reactive 
astrocytes, plasma cells, eosinophils and a few scattered neutrophils. 
Congestion and marked perivascular infiltrations composed of 
lymphocytes, plasma cells, macrophages and eosinophils were a common 
finding. Vasculitis and necrosis of vascular endothelium was found 
in several individuals. The brain parenchyma had scattered microglial 
nodules. Satellitosis and neuronophagia were noted In most affected 
areas. Eosinophilic Intranuclear inclusion bodies were rarely seen in 
neuroglial and endothelial cells. Variable degrees of agonal swelling 
were noted in the trigeminal nerve. Figures 6 to 9 Illustrate some 
of the lesions previously described. 
In the pigs killed at 60 days AC, the lesions in the CNS were 
characterized by mild to moderate perivascular infiltrations of 
lymphocytes, macrophages, plasma cells and a few eosinophils. No 
lesions were observed in the pigs from group II killed 60 days AC. 
Turbinates 
There were focal to diffuse areas of coagulatlve necrosis 
involving the epithelium and lamina propria. The necrotic 
areas were infiltrated by lymphocytes, macrophages, neutrophils, 
plasma cells and eosinophils. In some individuals, large amounts 
of purulent exudate and fibrin were present in the mucosa of the 




The lungs had multifocal areas of coagulatlve necrosis that 
involved the interstitium, bronchioles, and bronchi. The necrotic 
foci contained large amounts of fibrin with extensive infiltrations 
of lymphocytes, macrophages, plasma cells, eosinophils and a few 
scattered neutrophils. The alveoli were heavily infiltrated by the 
same types of Inflammatory cells. Focal areas of atelectasis were 
commonly seen. Large amounts of eosinophilic homogeneous protelnaceous 
material and fibrin filled the alveoli (Figure 11). The bronchlolar 
and bronchial epithelia were covered with large amounts of purulent 
exudate (Figure 12). 
Eosinophilic and basophilic Intranuclear inclusion bodies were 
present in alveolar pneumocytes, and in bronchial and bronchlolar 
epithelial cells (Figures 12 and 13). 
Severe vasculitis with endothelial necrosis was commonly 
observed in small vessels of the alveolar septa. 
Marked perivascular infiltrations of lymphocytes, macrophages, 
plasma cells and few neutrophils were commonly seen in affected areas. 
The tracheobronchial lymph nodes were characterized by congestion 
in the cortex and medulla with focal areas of coagulatlve necrosis 
in the cortex. 
Tonsils 
The lesions in the tonsils were characterized by multifocal 
areas of coagulatlve necrosis that involved the stratified squamous 
42 
epithelium of the crypts and adjacent lymphoid tissue. The 
necrotic areas were infiltrated by large numbers of lymphocytes, 
macrophages, plasma cells and eosinophils. Eosinophilic and basophilic 
Intranuclear inclusion bodies were seen. The eosinophilic inclusions 
were characterized by elongated large acidophilic Intranuclear 
bodies surrounded by a well-defined halo and marked marglnation of 
nuclear chromatin. These inclusions were seen only in the stratified 
squamous epithelial cells which were still attached to the epithelium 
(Figure 14). The second type of inclusion was basophilic and was 
characterized by a large homogenous mass of basophilic material 
which filled the nucleus. These nuclei had marked marglnation of 
chromatin. The basophilic inclusions were seen almost exlusively 
within the desquamated epithelial cells in the necrotic foci 
(Figure 15). 
Mandibular lymph nodes 
The lesions in the mandibular lymph nodes were rare and were 
characterized by mild congestion, edema and hemorrhages in the 
cortex and medulla. 
Some Individuals had a marked infiltration of eosinophils 
throughout the nodes. 
Analysis of data 
At 7 days AC, the lesion scores in the brain, turbinates, lung, 
bronchial lymph nodes and mandibular lymph nodes were generally 
significantly higher (P < 0,5) for the PI injected pigs when compared 
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to either the MLPRV or the IPRV vaccinated pigs. No significant 
difference was noted in lesion scores between the MLPRV and the 
IPRV vaccinated pigs (Tables 5 and 6). 
Exceptions In the CNS were found in the cervical and sacral 
spinal cord where no significant difference was detected among the 
PI, IPRV and MLPRV treated pigs and in the pons where the MLPRV 
vaccinated pigs had higher lesion scores than the IPRV vaccinates 
(P < .05). 
The exceptions in other tissues were found in the tonsils and 
lungs where no significant difference between the treated pigs 
was observed and in the turbinates of the IPRV vaccinated pigs 
which had higher lesion scores (P < .05) than the MLPRV vaccinated 
pigs (Table 6). 
At 60 days AC, no significant difference in lesion score was 
noted in any tissue among the different treatment groups (Tables 
7 and 8). 
Pigs In challenge groups I, III and IV had lower lesion score 
means than challenge groups V, VI and VII. None of the non-challenged 
pigs added In challenge groups V, VI and VII had microscopic lesions 
in any of the tissues examined. 
Electron Microscopy 
Hematoxylin and eosln stained paraffin sections 
Virus particles were demonstrated in some of the selected 
sections from the hematoxylin and eosln stained sections. Virus 
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particles were seen exclusively in the epithelial cells of the 
tonsilar crypts and were located in the nucleus, cytoplasm and 
intercellular space. Virus was present only in those cells 
which had the eosinophilic type of inclusion bodies. Mature 
virions were present outside the nucleus, while Immature virus 
particles were observed within the nucleus. The mature virions 
were characterized by an Icosahedral nucleocapsid surrounded by 
an envelope, while the immature particles lacked an envelope. 
Budding of virus particles through the nuclear membrane was 
common. The cells which contained the viral particles had marked 
margination of nuclear chromatin (Figure 16). 
Dense dispersion of nuclear chromatin in a basophilic type of 
inclusion is illustrated in Figure 14. 
Sections fixed in glutaraldehyde 
No virus particles or lesions could be demonstrated in any 
of the sections processed by this method. 
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DISCUSSION 
Neither the MLPRV vaccine nor the IPRV vaccine prevented 
infection or development of microscopic lesions in vaccinated 
pigs challenged with a virulent strain of PKV. However, vaccination 
diminished the severity of clinical illness and microscopic 
lesions for a period of 8 months after vaccination. 
The lower lesion scores in the CNS, turbinates, tonsils, 
lungs, bronchial lymph nodes and mandibular lymph nodes of vaccinated 
pigs in challenge groups I, III and IV and the increase in lesion 
scores of all vaccinated pigs in challenge groups V, VI and VII 
indicate a progressive decline in immunity beginning at month 8 
after vaccination for both the MLPRV and the IPRV vaccines. All 
the pigs in challenge groups V, VI and VII had similar lesion scores 
regardless of the type of vaccine received. 
The two vaccines provided similar protection against the 
development of microscopic lesions. 
Microscopic lesions in the CNS were found consistently 
throughout the study. The most common lesions were the presence 
of a lympho-hystlocytic-eoslnophillc perivascular infiltration 
and the formation of microglial nodules in the white and gray 
matter of the CNS. This is in agreement with the reports of previous 
authors concerning lesions in pigs challenged after vaccination 
with Inactivated and attenuated PRV vaccines. 
The most severely affected areas in the brain were the cerebral 
cortex at the level of the olfactory nerve and optic chiasma, mid brain. 
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thalamus, pons, medulla, trigeminal nerve and trigeminal ganglia. 
Lesions in these areas of the brain were expected since the 
pathogenesis of PRV involves the movement of the virus from the 
nasal cavity via the olfactory nerves to the olfactory bulbs and 
from the pharyngeal mucosa to the pons and medulla via the 
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trigeminal nerve. 
The vomiting seen in some of the vaccinated and non-vaccinated 
pigs can be attributed to the direct stimulation of the vomiting 
centers in the nucleus tractus solitarius and surrounding reticular 
formation or to stimulation of the glossopharanygeal nerve produced 
by the inflammatory reaction associated 'with the virus in the medulla. 
The presence of lesions in the brain 60 days AC may be due to a 
slow healing process in the CNS and probably the persistence of low 
numbers of PRV. 
Intranuclear inclusion bodies were extremely rare and when found 
were located in neuroglial cells and endothelial cells of small 
vessels. This is in agreement with reports by other authors 
O 1 Q 
working with strains of PRV found in the United States. ' In 
contrast to these results are those of European workers who have 
found the presence of inclusion bodies more often with European 
strains of 
22 
McTerran and Dow noted the presence of intranuclear 
inclusion bodies of Cowdry's type A in neurons, astrocytes and 
oligodendroglla in the cerebral cortex and sub-cortical white 
matter of non-vaccinated PRV infected swine. 
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The distribution of lesions in the CNS and upper and lower 
respiratory tract indicates that the Iowa strain of PRV replicates 
throughout those structures regardless of vaccination. 
The microscopic lesions observed in the tonsils, turbinates, 
lung and mandibular lymph nodes are in agreement with the lesions 
26 27 28 described by other authors. ' ' The only exception was the 
absence of Intranuclear inclusion bodies in the turbinates and 
lymph nodes of the pigs in this experiment. 
The observation that the eosinophilic inclusion bodies were 
mainly in the epithelial cells that were still attached to the 
epithelium of the crypts, bronchi and bronchioles and the demonstra­
tion of virus particles in these cells in the tonsils indicated that 
this type of inclusion is of viral origin. In contrast to this is 
the basophilic type of inclusion which was found mainly in the 
desquamated epithelial cells located within the necrotic foci in 
the lumens of the tonsilar crypts. Several attempts to demonstrate 
virus particles in these inclusions were unsuccessful which 
suggests that the basophilic type of inclusion is either an advanced 
stage of the eosinophilic type which does not contain a significant 
number of virus particles but rather an accumulation of viral 
proteins or just degenerated nuclear chromatin. 
The minimal mortality in this experiment (1 out of 93 pigs) 
was attributed to the natural resistance of older swine to PRV 
infection rather than to protection due to vaccination, since only 
one IFRV vaccinated pig died while no mortality was observed in the 
48 
PI injected pigs. The dead pig had a mild lympho-histiocytic 
meningoencephalitis and no lesions outside the CNS. Attempts to 
Isolate PKV or bacteria were unsuccessful. The cause of death 
could not be accurately determined however; on the basis of the 
microscopic lesions it is likely that the pig died of an acute PRV 
Infection. The death of this pig was attributed to an Individual 
low resistance to the virus. The absence of liver lesions in pigs 
from all groups can be attributed to the same age resistance factors. 
The absence of clinical signs and low lesion scores in all the 
pigs in challenge group II can not be explained. However, it 
was noted that the virus used to Infect this group was frozen and 
thawed twice and this treatment may have reduced the virus titers 
in the Inoculum and therefore diminished the severity of clinical 
signs and lesions. 
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Table 3. Mean body temperatures from day 1 to day 6 AC (pigs 
killed at 7 days AC) and from day 1 to day 8 (pigs 
killed at 60 days AC). 
Treatment N 
Pigs killed at 
7 days AC N 
Pigs killed at 
60 days AC 
PI solution 14 40.61* 14 40.19* 
IPRV vaccine 14 40.53* 14 39.93^ 
MLPRV vaccine 14 40.29^ 14 39.94^ 
^'^Same letter = no significant difference; different letter = 
significant difference (P < .05). 
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Table 4. Mean body temperatures by treatment group and challenge 
group, day 1 through 8 AC 
Challenge 
group PI solution IPRV vaccine MLPRV vaccine 
I 40.40 40.49 40.44 
II 39.34 39.35 39.43 
III 40.48 40.20 40.27 
IV 40.66 40.64 40.62 
V 40.30 39.80 39.62 
VI 39.52 39.26 39.17 
VII 39.85 39.78 40.07 
Table 5. Mean lesion scores In the CNS of pigs killed at 7 days AC 
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PI 14 1.80* 1.77* 1.78* 1.68* 1.59* 1.55** 2.06* 1.15** 1.18** 1.13** 1.25* 1.92* 1.24** 
IPRV 14 1.33^ 1.27^ 1.24^ 1.21^ 1.19^* 1.41^ 1.63^ 1.06^ 1.09^ 1.06^ 1.04^ 1.48^ 1.07^ 
MLPRV 14 1.15^ 1.19^ 1.20^ 1.18^ 1.29^* 1.33^ 1.57^ 1.04^ 1.09^ 1.05^ 1.06^ 1.39^ 1.04^ 
a,b,c,*g^^ letter = no significant difference; different letter = significant difference 
(P < .001); different letter* = significant difference (P < .05). 
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Table 6. Mean lesion scores in tissues outside the CNS of pigs killed 
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Table 7. Mean lesion scores in the CNS of pigs killed at 60 days AC 
1 Â , 0) 60 
h R. ? ? S 
§5 SI IS § S I A 2 1 
I  .  I  f c i t i  1 1  n  i  1 1  i  1 1  
PI 14 yes 1.04* 1.09* 1.04* 1.04* 1.04* 1.04* 1.12* 1.00* 1.00* 1.00* 1.02* 1.05* 1.00* 
IPRV 14 yes 1.04* 1.02* 1.00* 1.00* 1.00* 1.04* 1.05^ 1.00* 1.01* 1.00* 1.00* 1.00* 1.00* 
MLPRV 14 yes 1.00* 1.00* 1.01* 1.01* 1.07* 1.05* 1.23* 1.00* 1.02* 1.00* 1.00* 1.15^ 1.00* 
PI 3 no 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 
IPRV 3 no 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 
MLPRV 3 no 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 1.00* 
â b 
' *Same letter = no significant difference; Different letter = significant difference at 
the P < .05. 
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Table 8. Mean lesion scores in tissue outside the CNS of pigs killed at 
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PI 14 yes 1.05* 1.00* 1.01* 1.25* 
IPRV 14 yes 1.05* 1.01* 1.04* 1.14* 
MLPRV 14 yes 1.00* 1.03* 1.03* 1.13* 
PI 3 no 1.00* 1.00* 1.00* 1.00* 
IPRV 3 no 1.00* 1.00* 1.00* 1.00* 
MLPRV 3 no 1.00* 1.00* 1.00* 1.00* 
*Same letter = no significant difference; different letter = 
significant difference at the P < .05. 
Figure 1. Body temperature means by treatment group (PI injected, IPRV and MLPRV vaccinated), days 
1 through 8 AC 
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Figure 2. Body temperature means of challenge groups I, II, III and IV, Days 1 through 8 AC 
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Figure 3. Body temperature means of challenge groups V, VI and VII, days 1 through 8 AC 
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Figure 4. Turbinates from a PI injected pig killed at 7 days 
AC. Note purulent exudate in ventral concha (arrow) 
Figure 5. Lung from a PI injected pig killed at 7 days AC. 
Note areas of congestion and pneumonia in the cardiac 
(arrows) and diaphragmatic lobes 
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Figure 6. Trigeminal nerve of a PI injected pig killed at 7 days AC. 
Compare the large areas of necrosis and malacia (A) with 
the relative normal nervous tissue (B). Inset : higher 
magnification of an area similar to A, note the inter­





Figure 7. Medulla of a PI injected pig from challenge group I killed 
at 7 days AC. The lesion is characterized by a marked 
perivascular infiltration of mixed types of inflammatory 
cells. Note an eosinophilic intranuclear inclusion body 
(arrow) 
Figure 8. Thalamus of an IPRV vaccinated pig from challenge group VI 
killed at 7 days AC. Note a microglial nodule with 
neuronophagia (arrow) 
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Figure 9. Cerebral cortex at the level of the olfactory bulb of a 
PI injected pig from challenge group I killed at 7 days 
AC.Note diffuse necrosis and malacia. Inset: higher 
magnification showing a reactive astrocyte and a gitter 
cell (arrows) 
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Figure 10. Turbinates from a PI injected pig from challenge group III 
killed at 7 days AC. Note diffuse necrosis of the epi­
thelium (A) with inflammatory cells in the lamina propria 
(B). Inset : higher magnification of an acute inflammatory 
reaction with necrosis of the epithelium 

Figure 11. Lung from a MLPRV vaccinated pig from challenge group V 
killed at 7 days AC. Note large amounts of edema in the 
alveoli (A), necrosis of the alveolar septa (B) and 
fibrinonecrotic material in the lumen of a blood vessel 
(arrow) 

Figure 12. Bronchi from a MLPRV vaccinated pig from challenge group III 
killed at 7 days AC. Note large amounts of necrotic debri 
in the lumen (arrows). Inset; higher magnification of an 
eosinophilic intranuclear inclusion body in a bronchial 




Figure 13. Lung from a MLPRV vaccinated pig from challenge group III 
killed at 7 days AC. Note large amounts of homogeneous 
material in alveoli (A) and a focal area of necrosis in 
the alveolar septa (B). Inset: higher magnification of an 
area close to A, note an eosinophilic intranuclear inclusion 
body (arrow) 
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Figure 14. Tonsils of an IPRV vaccinated pig from challenge group I 
killed at 7 days AC. Note necrotic debri in the lumen of 
the crypt (arrow). Inset; higher magnification, note the 
large intranuclear eosinophilic inclusion, bodies in the 
epithelial cells with margination of chromatin (arrows) 
78 
mm 
Figure 15. Tonsils of an IPRV vaccinated pig from challenge group VI 
killed at 7 days AC. Note large amounts of necrotic debri 
in the lumen of the crypt (A). Inset: higher magnification 
of the basophilic type of inclusion bodies (arrows) 
00 
Figure 16. Tonsillar epithelial cell containing an eosinophilic type of 
intranuclear inclusion. Note -marked margination of nuclear 
chormatin (arrows). 18620X. Inset: immature viral particles 
about to budd through the nuclear membrane (arrow) and 
mature virions in the cytoplasm. 133000X 
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Figure 17. Basophilic type of inclusion (tonsil). Note the electron 
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• SUMMARY 
The effects of vaccination against pseudorabies virus infection 
were studied in 93 castrated male pigs. The pigs were divided into 7 
groups and challenged with a virulent strain of pseudorabies virus 
at 1, 3, 5, 8, 10, 12 and 14 months after vaccination. Federally 
licensed modified live and inactivated pseudorabies virus vaccines 
were used as the immunizing agents. The levels of cellular and 
humoral immunity were measured after vaccination and after challenge. 
Virus isolation was attempted at different time intervals after 
challenge. 
Both vaccines induced a detectable primary humoral immune 
response that lasted for several months after vaccination. However, 
vaccination failed to induce a detectable first type cell-mediated 
immune response when measured by the lymphocyte transformation test 
from months 1 to 16 after vaccination. The vaccines induced a detectable 
secondary response after challenge at the humoral and cellular level 
for a period of 14 months after vaccination. 
The secondary levels of humoral immunity declined 8 months 
after vaccination, while the cellular immunity remained high for 16 
months after vaccination. 
The modified live pseudorabies virus vaccine induced higher 
levels of humoral and cellular immunity than the inactivated type 
however, the protection conferred against challenge was equal for both 
types of -vaccines. 
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The cell-mediated immune response is useful in predicting early 
and late response to challenge in vaccinated and non-vaccinated pigs. 
Swine vaccinated with either type of vaccine may give false 
negative virus isolation results when tested after infection with a 
virulent strain of pseudorabies virus. 
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INTRODUCTION 
The phenomenon of cell-mediated immunity (CMI) can be evaluated 
by the effects of specific antigens on lymphocytes ^  vitro.^ 
Generally thymus derived lymphocytes (T cells) are responsible 
for this reaction, however, cells derived from the stem cells of 
the bone marrow (B cells) also may play an important role.^'^'^'^ 
The blast transformation test measures the ^  vitro proliferative 
response of previously sensitized T cells to a specific antigen. 
3 
The test indicator system is the degree of incorporation of H thymidine 
into nuclear deoxyribonucleic acid (DNA).^^ The use of the iji vitro 
lymphocyte transformation assay as a method of detecting the cell-mediated 
immune response in swine infected with pseudorabies virus (PRV) has 
been recently reported.The lymphoproliferatlve response of 
lymphocytes sensitized to a Shope strain of PRV antigen was demonstrated 
to occur 6 days after challenge with a virulent strain of PRV. The 
response was detected in the lymphocytes from the peripheral blood 
g 
of non-immune swine. In the same work the presence of humoral antibody 
was first observed 8 days after challenge. An earlier lymphoproliferatlve 
response in swine lymphocytes was demonstrated 4 days after challenge 
with a Phylaxia strain of PRV. Humoral antibodies were first detected 
7 days after challenge. The lymphoproliferatlve response was still 
9 
present 35 days after challenge. Swine vaccinated with a modified live 
PRV vaccine were shown to have a positive lymphoproliferatlve response 
between days 7 and 14 after vaccination and the response lasted for a 
period of 174 days.^^ 
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The objectives of this study were: 1) to determine if cellular 
immunity is useful in predicting response to challenge and potential 
for carrier animals; 2) to determine the degree of protection due to 
cellular and humoral immunity in pigs vaccinated with two commercially 
available PRV vaccines; and 3) to determine the effects of vaccination 
on virus isolation, fluorescent antibody and virus tissue co-culture 
tests. 
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MATERIALS AND METHODS 
Animal and Specimen Preparation 
The specifics of the experimental design were described in 
previous work.Briefly, ninety-three seven week old castrated male 
pigs were utilized. The animals were free of clinical atrophic rhinitis 
and of serologic evidence of pseudorabies, transmissible gastroenteritis 
and leptospirosis. The pigs were divided in treatment groups based 
on time of challenge (I, II, III, IV, V, VI, VII). 
Groups I, II, III and IV consisted of 4 pigs vaccinated with a 
modified live PRV (MLPRV) vaccine,* 4 pigs vaccinated with an inactivated 
PKV (IPRV) vaccine^ and 4 pigs Inoculated with a placebo (PI) solution. 
Groups V, VI and VII consisted of 5 pigs of each category (5 MLPRV 
vaccinated, 5 IPRV vaccinated and 5 PI injected). 
All the pigs were vaccinated simultaneously at 9 weeks of age 
and then allowed to commingle evenly in three large pens each until 
90 days after immunization. 
The level of cell-mediated immunity was measured by the use of 
a lymphocyte transformation assay ^  vitro. The test was performed 
before challenge and at 6 days after challenge in half of the animals 
in each group and 5 times in the other half (before challenge and 
at 6, 11, 36 and 60 days after challenge) (Figure 1). The level of 
humoral immunity was determined by the microtitration serum 
*Norden Laboratories Inc., Lincoln, Nebraska 68501 U.S.A. 
^Salisbury Laboratories. Charles City, Iowa 50616 U.S.A. 
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neutralization test (Figures 2, 3). All the serums collected during 
the first 8 months after vaccination (groups I, II, III, and IV) were 
tested simultaneously, while the serums collected during the following 
8 months after vaccination (groups V, VI, and VII) were tested 
separately at monthly intervals (Figures 2, 3). In the challenged 
animals the test was performed at 7 days AC in half of the animals 
and at 60 days AC in the other half-
Virus isolation from the brain and spleen and fluorescent antibody 
test from the lungs, tonsils and trigeminal ganglia were performed 
on all the pigs killed at 7 and 60 days AC. Virus co-culture from the 
trigeminal ganglia was conducted only in the pigs killed at 60 days AC. 
Sections from the lungs, liver, kidney, mesenteric lymph nodes, 
colon and swabs from the nasal turbinates and brain were collected for 
bacteriologic examination. 
Virus propagation and animal inoculation 
Virus propagation and animal inoculation were described in detail 
in a previous work.^^ Briefly, an Iowa strain of PRV at the 10^^ and 
11^^ tissue culture passage containing 1.6 x 10^ and 5 x 10^ plaque 
forming units respectively, was used as the inoculum. The pigs were 
inoculated intranasally with 4 ml of the virus by the use of a sterile 
canula and syringe. 
Pseudorabies virus antigen preparation 
The technique to prepare the virus antigen used in this experiment 
12 
was the same as described by previous workers. A field isolate of 
an Iowa strain of PRV at the 10^^ tissue culture passage containing 
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1.6 X 10^ plaque forming units was propagated in PK-15 cells, the 
cells were frozen, thawed and sonicated. The virus was precipitated 
by the addition of 42.5 g/100 ml of ammonium sulphate and concentrated 
by centrifugation and addition of polyethylene glycol (Mol. wt. 20,000). 
The viral antigen was inactivated by the addition of 0.3% beta 
propiolactone.^ Lack of residual infectivity was verified by inoculation 
of 1 ml of the final viral antigen solution into PK 15 cell cultures. 
The virus was considered inactivated if no cytopathic effect was 
observed 96 hours after inoculation. 
Lymphocyte transformation assay iji vitro 
The technique used for the lymphocyte transformation test was the 
g 
same as implemented by previous workers. Blood was collected from the 
anterior vena cava into siliconized tubes containing 10 units of 
heparin/ml. The mononuclear cells were separated and a dilution 
containing 4.7 x 10^ cells/ml prepared. One hundred and fifty pi of 
cells were added to each well of a 96 well U bottom microtiter plate. 
The concentrated antigen was diluted 1 to 80 and 50 yl of the 
diluted antigen added to each well. The control wells received 
50 yl of RMPI 1640 media while the positive control wells received 
3 10 yg of phytohemagglutinin P (PHA-P). H thymidine was added and 
the cells harvested onto glass fiber filter paper. The samples were 
counted in a liquid scintillation counter.^ The results were expressed 
^ Packard Tricarb Model 2425 Liquid Scintillation Spectrometer 
System, Downers Grove, IL. 
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in counts per minute (cpm) and stimulation ratios which were the 
division of the cpm of the cells containing the PRV antigen by the 
cpm of the cells containing the control media (RMPI 1640). Each 
sample was set up in 6 wells. 
Microtltratlon serum neutralization test 
The technique used to detect humoral antibodies wâs the same 
13 described by previous authors. 
Virus isolation 
The technique used for virus isolation was the same as described 
13 by previous investigators. 
Half of the brain and spleen was ground, a 20% tissue suspension 
was obtained by adding Earle's balanced salt solution containing 0.5% 
lactalbumin hydrolysate and antibiotics. The suspension was 
centrifuged and the supernatant used to inoculate monolayers of PK-15. 
The cell cultures were incubated for 96 hours to check for the presence 
of cytopathic effect (CPE). 
Fluorescent antibody test 
The technique used to demonstrate the presence of viral antigen 
13 has been described in detail. 
Sections of tonsils, lungs and trigeminal ganglia were frozen and 
sections 6 microtiters in thickness were fixed in acetone flooded with 
a fluorecein-labelled PRV conjugate, incubated, rinsed and examined 
with an Orthoplan research microscope with 200 watt mercury vapor lamp, 
HBO 200.3 
3 E. Lietz, New York, NY. 
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Virus co-culture 
The technique used to demonstrate viral particles from the 
trigeminal ganglia was the same as described in a recent publication.^^ 
Small sections of trigeminal ganglia measuring 1 mm were collected 
by the use of sterile scissors and forceps, the tissues were placed 
in 2 ml of minimum essential medium containing 2% fetal calf serum 
and antibiotics. The fragments were placed on a monolayer of Madin 
Darby bovine kidney (MDBK) cells. The cells were incubated at 37°C in 
a 5% COg atmosphere and checked every day for a period of 8 days for 
the presence of cytopathlc effects. The tissue fragments were transferred 
to fresh cell culture monolayers every 96 hours. 
Bactériologie examination 
The bacteriologlc examinations were conducted by the use of 
conventional techniques. Blood agar was used as the culture medium 
for the lungs, turbinates, brain swabs and nasal swabs. The colon, 
mesenteric lymph nodes, kidney, spleen and liver were cultured 
on brilliant green agar. 
Data evaluation 
The lymphocyte transformation assay was evaluated according to 
8 10 
the criteria established by previous authors * who Indicated that 
stimulation ratios above 3 to 1 are significant for a positive lympho-
prollferative response, while ratios below 3 to 1 are not significant 
and therefore considered negative. By the use of the student T test^^ 
.98 
the stimulation ratios between the PI Injected, the IPRV vaccinated 
and the MLPRV vaccinated pigs were compared. 
The serum neutralization test was considered positive at the 
dilution of 1:2 or greater, while the fluorescent antibody test, the 
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Lymphocyte transformation test 
The stimulation ratios after vaccination and before challenge 
were lower than 3 to 1 In the great majority of the pigs. The 
stimulation ratios began to Increase after challenge. The response 
was first detected and reached Its highest value at 6 days AC and 
remained at a high level for a period of 60 days regardless of the 
type of vaccine received. 
The pigs which received the MLPRV vaccine had the overall 
highest stimulation ratios followed by those which received the IPRV 
vaccine and the PI solution, respectively (Figure 4). The non-
challenge vaccinated pigs had negative stimulation ratios throughout 
the experiment. 
Table 1 Illustrates the overall lymphocyte stimulation ratios 
between the different types of vaccines in the challenge and 
non-challenge animals. 
The stimulation ratios in the animals challenged at months 1, 3 
and 5 after vaccination (challenge groups I, II and III) did not show 
a consistent pattern throughout the days following challenge while 
those pigs challenged at months 8, 10, 12 and 14 (groups IV, V, VI 
and VII) had a consistent Increase in stimulation ratios following 
challenge. 
Table 2 illustrates the stimulation ratios divided by group and 
type of vaccine received. 
103 
The pigs which received the MLPRV vaccine had overall stimulation 
ratios of 9 to 1 throughout the experiment, while the pigs which 
received the IPRV vaccine had overall stimulation ratios of 6,6 to 
1 AC. The PI injected pigs had the lowest overall stimulation ratios 
of 4.6 to 1 AC. 
The vaccinated non-challenge pigs had overall stimulation ratios 
lower than 1.2 to 1 regardless of the type of vaccine received (Table 
1, Figure 4). 
The highest percent of animals with ratios greater than 3 to 1 
was found at 6 days AC in the MLPRV vaccinated pigs and at 11 and 6 
days AC in the IPRV vaccinated and PI injected, respectively (Table 
2, Figure 5). 
In most samples the counts per minute of the cells exposed to the 
mitogen PHA-P were about 27 times higher than the RMPI 1640 exposed 
cells or 7 times higher than the PRV antigen exposed cells in the PRV 
infected animals and 10 to 80 times higher in the non-infected pigs. 
Overall mean counts per minute for the different types of 
vaccinated pigs (challenge and non-challenge) are illustrated in 
Table 3. The mean counts per minute divided by groups are illustrated 
in the Appendix of the senior author's Ph.D. dissertation.^^ In the 
challenge animals the MLPRV vaccinated had the highest counts per 
minute in the cells which received the PRV antigen and the RMPI 
1640 media, followed by the IPRV vaccinated and the PI injected, 
respectively. 
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The PI injected pigs had the highest counts per minute in the 
/• 
cells which received the mitogen PHA-P, followed by the MLPRV and 
IPRV vaccinated. 
Serum neutralization test 
None of the PI injected animals were seropositive before 
challenge. The highest percent of seropositive results in the pigs 
that received the IPRV vaccine was 84% at 2 months after vaccination, 
while those pigs which received the MLPRV vaccine had the highest 
seropositive results of 90% at two months after vaccination. In both 
cases, the percent of pigs that were seropositive began to decline 
gradually 2 months after vaccination (Table 7). The pigs which received 
the MLPRV vaccine had an average of twice the level of antibody titers 
(4 to 2) than the IPRV vaccinated pigs before challenge. 
Only 21% of the PI injected pigs were seropositive at 7 days AC, 
while the pigs which received the IPRV and MLPRV vaccine did so at 
the 100 to 85% levels, respectively. 
The percent of seropositive animals at 60 days AC was 86% for all 
these groups (Table 4, Figure 6). 
Table 5 and Figure 4 illustrate the number of animals that were 
seropositive in the different groups at 7 and 60 days AC. 
At 7 days AC, the animals that received the MLPRV vaccine had the 
highest antibody titers followed by the pigs that received the IPRV 
vaccine and the PI solution, respectively. 
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At 60 days AC, the pigs that received the IPRV vaccine had the 
highest antibody titers followed by the MLPRV vaccinated and the PI 
injected, respectively (Table 5). 
The vaccinated pigs in groups I, III and IV had the highest 
serum neutralization titers, while groups II, V, VI and VII had 
the lowest. 
All the non-challenge pigs were negative throughout the experiment. 
The serum neutralization titers divided by challenge group are 
illustrated in the Appendix of the senior author's Ph.D. dissertation.^^ 
Virus isolation 
In the PI injected pigs, PRV was isolated in 6 out of 14 (43%) of 
the pigs killed at 7 days AC, while in the pigs killed at 60 days AC 
virus was isolated only in 1 out of 14 (7%). Virus was isolated from 
only 1 out of 14 (7%) of the IPRV vaccinated pigs at 7 days AG, and no 
virus was isolated 60 days AC. 
In the MLPRV vaccinated pigs, virus was detected in only 1 out of 
14 (7%) of the pigs killed at 7 and 60 days AC, respectively. 
All the non-challenge pigs were negative at 7 and 60 days AC 
(Table 6). 
Fluorescent antibody test 
In the PI injected pigs, the fluorescent-antibody test (FAT) was 
positive on tonsils in 7 out of 14 (50%) of the pigs and 1 out of 14 (7%) 
of the lungs and trigeminal ganglia of pigs killed at 7 days AC. 
All the pigs tested at 60 days AC were negative. 
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All tissues were negative in the IPRV pigs at 7 or 60 days AC. 
Five out of fourteen (36%) of the MLPRV vaccinated pigs tested at 7 
days AC had positive results in the tonsils, while no positive results 
were obtained at 60 days AC. 
All non-challenge pigs were negative at 7 and 60 days AC 
(Table 6). 
Virus co-culture 
All the attempts to isolate PRV by co-culture from the trigeminal 
ganglia were unsuccessful. 
Bacteriologic examination 
Except for the usual flora no bacteria were Isolated from the 
lungs, brain, liver, colon, spleen, kidney and mesenteric lymph nodes. 
The results of each of the tests mentioned above divided by 




Results obtained in this experiment indicate that both 
vaccines induced a primary humoral immune response detectable for a 
period of 8 and 13 months after vaccination with the IPRV and MLPRV 
vaccines respectively. The secondary levels of humoral and cellular 
immunity detected AC were higher in the vaccinated challenged pigs than 
in the challenged controls. The minimum levels of cellular immunity 
following vaccination before challenge suggests that a first type cell-
mediated immune response occurred with both vaccines, however, because 
this response was measured at 30, 90, 150, 240, 300 and 420 days after 
vaccination it is likely that the levels of cellular immunity were low 
and therefore were not accurately detected by the lymphocyte trans­
formation test. This observation can be compared with a previous report^' 
in which the authors demonstrated a positive lymphoproliferative 
response at days 4, 7, 11 and 21 after vaccination with a MLPRV vaccine.^ 
The MLPRV vaccinated pigs had a higher and longer lasting primary 
humoral response than those pigs which received the IPRV vaccine, 
however, this response declined sharply in titer and in percent of 
reactors at 7 months after vaccination. The protection conferred by 
vaccination was attributed to a primary humoral immune response following 
vaccination and rapid development of a secondary type of immune response 
at the humoral and cellular levels after challenge. This conclusion 
was reached because the primary levels of cellular immunity were only 
^ Dulphar, Aujeszky vaccine Philips Dulphar, Amsterdam, The 
Netherlands. 
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detected in a very low number of individuals after vaccination and 
before challenge, while levels of both types of immunity were high 
after challenge. When the primary and secondary levels of humoral 
immunity were high in groups I, III and IV, adequate protection 
against challenge was observed in spite of the moderate levels of a 
second type of cellular immunity. However, when the primary levels 
of humoral immunity began to decline in groups V, VI and VII 
protection against challenge was absent. The levels of secondary 
humoral immunity AC in these groups was low. In contrast with this 
were the levels of secondary cellular immunity AC which reached higher 
values in these groups. This observation indicated that the greatest 
protection against challenge was the result of the high levels of 
primary humoral immunity rather than a secondary cellular response. 
This correlates with a previous report^^ in which the decline in 
immunity was observed at the same time intervals and was evaluated 
by the presence of clinical signs, gross lesions and microscopic lesions. 
The risk of transmission of vaccine virus associated with 
previous types of vaccines^^ was not observed in this experiment. The 
basis of this conclusion was that none of the placebo injected pigs 
developed serum neutralizing antibodies in spite of being penned 
together with the vaccinated pigs for several months beginning at 
month 3 after vaccination, thus indicating that the placebo injected 
animals were not infected by any type of pseudorabies virus. 
The variation in percent of seropositive pigs from month 9 to 
16 after vaccination could not be explained, however, it is to be 
noted that those samples were tested separately at monthly intervals 
which may have caused such variation. 
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The evaluation of cell-mediated immunity by the lymphocyte 
transformation test iji vitro is useful in predicting the early 
response to challenge, especially in non-vaccinated Individuals in 
which the primary humoral immunity develops within 7 to 8 days AC. 
In the vaccinated animals humoral and cellular immunity were 
detected for the first time at 6 and 7 days AC, respectively. 
The greater percentage of virus isolations from the pigs which 
received the PI injections (lowest levels of humoral and cellular 
immunity) and the low percentage of virus isolations from the 
vaccinated pigs (highest levels of humoral and cellular immunity) 
indicate that virus isolation attempts from vaccinated animals may 
give a negative virus isolation test. This may be attributed to a 
possible reduction or neutralization of viral particles by the high 
levels of humoral and cellular immunity. 
The failure to isolate the virus by tissue co-culture 
technique from the trigeminal ganglia may have been due to: a) the 
high levels of cellular and humoral immunity which persisted for longer 
periods of time AC, b) a low number of viral particles in the tissue 
at that time, c) a lack of sensitivity of this test to detect small 
numbers of viral particles or d) failure to maintain the culture 
for a sufficient period of time. These results are in disagreement 
with the reports by previous workers^^ who reported the isolation 
of PRV by tissue co-culture techniques from the trigeminal ganglia, 
tonsils and pools of trigeminal ganglia tissue and olfactory and 
optic nerves from six out of seven pigs 13 months after Inoculation 
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with an Iowa strain of PRV; however, it is to be noted that these 
workers incubated the tissue culture cells for 8 more days than 
in this experiment. 
Table 1. Overall stimulation ratios of porcine peripheral blood lymphocyte cultures from 



















































































yes 28-14* PI 1.2* 7.3*** 4.7*** 4.0*** 4.5*** 
yes 28-14 IPRV 1.3* 10.6^** 4.5*** 4.7*** 2.9* 
yes 28-14 MLPRV 1.6* 17.4^** 11.5b** 5.9*** 5.9*** 
no 3 PI 1.0* 1.0* 
(d 00 c
 0.6* 0.6* 
no 3 IPRV 0.8* 1.0* 1.1* 1.0* 1.3* 
no ; 3 MLPRV 1.1* 0.8* 0.8* 1.9* 0,7* 
*The 'TRV challenge groups at pre-challenge and at 6 days after challenge contained 28 pigs each 
while at 11, 36 and 60 days after challenge they contained 14 pigs each. 
**Stimulation ratios above 3 are positive, below 3 are negative. 
*'^Same letter = no significant difference; Different letter = significant difference at the 
P < .05. 
Figure 4. Overall stimulation ratio means for challenge and non-challenge pigs; bottom line 
corresponds to the vaccinated non—challenge pigs 
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yes 28-14* PI 3.6 46.4 50.0 50.0 28.6 35.7 
yes 28-14 IPRV 3.6 50.0 92.9 57.1 21.4 45.0 
yes 28-14 MLPRV 3.6 85.7 64.3 64.3 50.0 53.6 
no 3 PI 0 0 0 0 0 0 
no 3 IPRV 0 0 0 0 0 0 
no 3 MLPRV 0 0 0 0 0 0 
*The PRV challenge groups at pre-challenge and 6 days after challenge contained 28 pigs each, 
while at 11, 36 and 60 days after challenge contained 14. 
Figure 5. Percent of pigs with stimulation ratios above 3 to 1 AC; bottom line corresponds 
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Table 3. Overall counts per minute means of the PRV challenge and non-challenge pigs 
after vaccination after vaccination at days 6, 



















































































































PI 1833 1831 85396 3490 15536 107309 
IPRV 1862 1830 98713 5075 17710 86264 
MLPRV 2398 2398 90505 6727 20735 95364 
non-challenge pigs 
PI 788 810 113237 1328 2772 184884 
IPRV 1992 1366 164427 2166 1967 149556 
MLPRV 1678 1159 274076 1568 1267 95199 
Table 4. Percent of seropositive^ pigs after vaccination 
vaccine 1 2 3 4 5 6 7 
months 
8 9 10 11 12 13 14 15 16 
PI 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
IPRV 84 45 57 47 20 23 31 10 0 0 9 0 0 0 0 0 
MLPRV 90 100 92 96 93 76 71 50 0 22 36 10 33 0 0 0 
^ >1:2 dilution 
Table 5. Percent of serpositive^ pigs after challenge 
vaccine number of pigs 7 days % number of pigs 60 days % 
PI 14 3 21 14 12 86 
IPRV 13 13 100 14 12 86 
MLPRV 14 12 85 14 12 86 
^ >1:2 dilution 
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Table 6. Fluorescent antibody and virus Isolation tests for pigs killed at 7 and 60 days after 
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> o "3 
PI 14 7 7 1 1 50 6 43 
IPRV 14 7000 01 7 
MLPRV 14 7 5 0 0 36 1 7 
PI 14 60 0 0 0 0 1 7 
IPRV 14 60 0 0 0 0 0 0 
MLPRV 14 60 0 0 0 0 1 7 
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GENERAL DISCUSSION AND CONCLUSIONS 
The modified live and inactivated pseudorabies virus vaccines 
used in this experiment conferred equal protection against challenge 
for a period of 8 months after vaccination. The modified live 
vaccine induced a higher humoral and cellular immune response; however, 
the difference in immunity did not significantly affect protection 
against challenge. This observation is in contrast with a previous 
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report in which the authors indicated that one dose of modified 
live vaccine gave better protection than two with an inactivated vaccine 
and that the inactivated vaccine did not confer complete protection 
against challenge. It Is to be noted however, that the vaccines 
utilized in their experiment were different than those utilized in 
this work. 
The observation that neither type of vaccine prevented infection 
after challenge in this experiment is in agreement with a previous 
report^^ in which the authors utilized other inactivated^ and modified 
live^ pseudorabies virus vaccines as the immunogens. 
The observation that vaccination diminishes the severity of 





The effects of vaccination on mortality rate in pigs 3 months of 
age or older were not significant in this experiment. This conclusion 
was reached on the basis that no control pigs over 3 months of age 
died after challenge. The first type humoral antibody response was 
more consistent in the MLPRV than in the IPRV vaccinated pigs after 
vaccination and before challenge. The fact that all IPRV vaccinated 
pigs were seronegative at month 8 and 9 after vaccination and then 
9% were seropositive at month 11 after vaccination could not be 
explained however; it was concluded that these pigs were never 
infected with a field strain of PRV virus before the experimental 
challenge because all the PI injected animals that were penned 
together with the IPRV and MLPRV vaccinated pigs before challenge were 
seronegative throughout the experiment. Another factor that may have 
contributed to this variation in serum neutralization results was 
the fact that the serum samples were not all tested at the same time. 
The risk of transmission of vaccine virus associated with previous 
79 
types of vaccines was not observed in this experiment. The basis 
of this conclusion was the same as mentioned above, that none of the 
placebo injected pigs developed serum neutralizing antibodies in 
spite of being penned together with the vaccinated pigs for several 
months beginning at month 3 after vaccination, thus indicating that 
the placebo injected animals were not infected by any type of 
pseudorabies virus. 
The negative results obtained by the lymphocyte transformation 
test after vaccination but before challenge may have been due to the 
following possibilities: a) that vaccination did not induce first 
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type cell-mediated immune response; b) that the first type cell-
mediated Immune response did occur but could not be detected 
because it was measured for the first time at 30 days after 
vaccination; c) that the lymphocyte transformation technique was 
not sensitive enough to detect the first type cell-mediated immune 
response after vaccination. Further investigations of possible 
transmission of vaccine virus with this type of modified live vaccine 
are needed. This can be achieved by the use of the lymphocyte 
transformation, serum neutralization, and ELISA tests as methods of 
detecting both primary humoral and cellular immune response from day 1 
to 10 in non-vaccinated animals penned simultaneously with recently 
vaccinated hogs. 
The low percentage of pigs with a detectable first type cell-
mediated immune response after vaccination in this experiment is in 
disagreement with a previous report^^ in which the authors detected 
a positive lymphoproliferative response in 3 month old pigs after 
vaccination. However, there were two major differences between these 
two experiments; 1) the vaccine used in the other experiment was 
prepared by a different laboratory* and 2) the cell-mediated immune 
response was measured at 0, 4, 7, 11, and 21 days after vaccination, 
while in this work the response was measured at 30, 90, 150, 240, 300, 
360 and 420 days after vaccination. 
The protection conferred by vaccination was attributed to a 
primary humoral immune response following vaccination and to a rapid 
* Dulphar, Aujeszky vaccine Philips Dulphar, Amsterdam, The 
Netherlands. 
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development of a secondary type of immune response at the humoral 
and cellular levels after challenge. This conclusion was reached 
because the primary levels of cellular immunity were only detected 
in a very low number of individuals after vaccination and before 
challenge. When the primary and secondary levels of humoral immunity 
were high in groups I, III, and IV, adequate protection against 
challenge was observed in spite of the moderate levels of a second 
type of cellular immunity. However, when the primary levels of 
humoral immunity began to decline in groups V, VI, and VII protection 
against challenge was absent. The levels of secondary humoral immunity 
AC in these groups was low. In contrast with this was the levels of 
secondary cellular immunity AC which reached higher values in these 
groups. This observation indicates that the greatest protection 
against challenge was the result of the high levels of primary humoral 
immunity rather than a secondary cellular response. The lack of 
consistency of the modified live vaccine to induce steady levels of 
circulating antibodies for long periods of time in a large number of 
individuals has been observed by other workers.The percent of animals 
with detectable primary humoral immunity after vaccination with the 
inactivated vaccine in this experiment is in agreement with a report 
91 by previous workers who indicated that 18 weeks after immunization 
with the same type of vaccine almost half of the 20 young vaccinated 
pigs were seropositive. In the present study at 16 weeks after 
vaccination 47% of the IPRV vaccinated pigs seroconverted. In the same 
work, the authors described a field study in which 96% of vaccinated 
sows were seropositive at 2 weeks after vaccination, while 88% of 
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seropositive results were observed in weaned pigs at 4 weeks after 
vaccination. In the present study 45% of the IPRV vaccinated pigs 
were seropositive at 4 weeks after vaccination. The discrepancies 
among these two experiments could not be explained because in spite 
of the low percent of animals with detectable primary immunity 
induced by the inactivated vaccine in this experiment a strong 
secondary response was detected after challenge at the humoral and 
cellular levels, thus ruling out the possibility of a defective 
vaccine lot. In addition, protection against challenge was present 
in the pigs vaccinated with the inactivated vaccine for a period of 
8 months after vaccination. 
The cell-mediated immune response proved to be a 50% reliable 
test for detecting early infection in non-vaccinated animals. In 
vaccinated pigs, the test reached a high percent of accuracy (86% in 
the inactivated and 93% in the modified live vaccine group) in 
detecting the early response to challenge. 
In this experiment, humoral immunity was a reliable test for 
detection of secondary exposure to the virus in vaccinated animals 
at 7 days after challenge. This conclusion was reached on the basis 
that 100% of the pigs vaccinated with the inactivated vaccine and 
85% of the pigs vaccinated with the modified live vaccine had an 
increase in titer at 7 days after challenge. The primary humoral 
response after challenge in non-vaccinated animais was detected in 
only 21% of the pigs at 7 days after challenge. 
The main disadvantage of the lymphocyte transformation test is 
that it is time consuming and expensive. However, improvements in the 
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technique such as shortening the Incubation period and using whole 
blood rather than purified lymphocytes could be valuable in increasing 
the practicality of this method. 
No side effects associated with vaccination were observed in this 
experiment, therefore it was concluded that both vaccines are safe 
for use in weaned swine. 
Because protection against challenge began to diminish 8 months 
after vaccination, revaccination with either type of vaccine is 
recommended at 7 months after vaccination. 
The Iowa strain of pseudorabies virus used in this experiment 
replicated readily at all the levels of the central nervous system 
and respiratory tract of vaccinated and non-vaccinated pigs and 
produced lesions at these sites similar to those produced by other 
9 50 60 12 32 
strains of European ' ' and American pseudorabies virus. ' 
One notable characteristic of the Iowa strain was the formation 
of large numbers of intranuclear inclusion bodies in the tonsils and 
lungs. However, the strain lacks the property of inducing a significant 
number of inclusion bodies in the central nervous system. Why the 
inclusions are present in the tonsilar and respiratory epithelium and 
not in the central nervous system in the majority of the pigs in this 
experiment cannot be explained. However, evidence has been accumulated 
which indicates that the presence, absence or frequency of inclusion 
bodies in the central nervous system is dependent on the virus strain 
1 J 43, 48 involved. 
g 
The observation by Corner that the basophilic type of inclusion 
may represent a more advanced stage of inclusion body development 
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was verified in this experiment. The basis for this conclusion was 
that the basophilic type of inclusions were seen mainly in the 
desquamated epithelial cells located within the necrotic debri in 
the lumen of the tonsillar crypts, and that several attempts to 
demonstrate viral particles in these inclusions by the use of 
electron microscopy were unsuccessful. Therefore, it was concluded that 
the basophilic type of inclusions did not contain viral particles but 
rather were formed by dispersion of nuclear chromatin and that they are 
a late form of the eosinophilic type of inclusion. On the other hand, 
the eosinophilic type of inclusions were considered to be true 
viral inclusions, since herpes viral particles were demonstrated in 
the tonsillar epithelial cells that contained eosinophilic inclusions. 
The histopathologic examination was the most consistent way to 
demonstrate the presence of the disease. This conclusion was reached 
because 100% of the vaccinated and non-vaccinated pigs killed at 7 
days after challenge had microscopic lesions in the central nervous 
system. The lesions were still present in 79% of the vaccinated and 
non-vaccinated pigs killed at 60 days after challenge, unfortunately 
similar lesions can be found in other types of viral encephalitides 
in swine such as hog cholera, African swine fever, hemaglutinating 
encephalomylitis virus infection and swine vesicular disease among 
others and therefore the presence of nervous lesions although 
suggestive can not be considered diagnostic for pseudorabies virus 
infection. 
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The presence of intranuclear inclusion bodies in the tonsillar 
epithelial cells in this experiment was considered strongly suggestive 
for pseudorabies virus infection. 
The low percent of positive results with the fluorescent anti­
body test in the modified live (36%) and inactivated vaccinated (0%) 
pigs after challenge and the low percent of virus isolation (7%) in 
pigs vaccinated with either type of vaccine illustrate that both 
tests alone are not reliable indicators of infection after vaccination; 
however, it is to be noted that body temperature in the infected pigs 
peaked between days 2 and 3 which may have indicated the 
highest viral replication rate at that time. The virus isolation 
and fluorescent antibody tests were attempted at 7 and 60 days AC 
and therefore, the possibility that only low quantities of virus, 
below the sensitivity of the isolation techniques employed, were 
present at that time and may have resulted in the low percent of 
positive results with both tests. 
The inoculation technique used in this experiment is highly 
recommended as a method of experimentally reproducing the disease. 
The deposit of virus suspension deep into the nasal cavity (5 cm) 
was 100% effective in achieving infection in vaccinated and non-
vaccinated pigs. 
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APPENDIX 
Table A-1. Stimulation ratios of porcine peripheral blood lymphocyte cultures from PRV exposed 
and non-exposed swlne divided by group; stimulation ratios above 3 are positive, 
below 3 are negative 
N time 
challenge pre- 6 days 11 days 36 days 60 days 













































































































0 .8  
1.4 
1.2 
2 .6  
0.9 
1.0 
2 .0  
12.0 
2.0  
4-2 10 IPRV V 0.7 
4-2 10 MLPRV V 1.2 
4-2 10 PI VI 0.8 
4-2 10 IPRV VI 0.8 
4-2 10 MLPRV VI 1.0 
4-2 10 PI VII 0.6 
4-2 10 IPRV VII 4.0 
4-2 10 MLPRV VII 0.7 
^ime = months after vaccination. 
6.3 3.0 4.0 2.0 
26.6 6.5 4.3 5.0 
7.0 8.4 12.2 1.9 
46.1 8.2 16.8 7.4 
70.6 26.8 16.2 0.9 
24.4 14.0 2.7 10.1 
12.1 3.2 1.6 3.1 
15.5 12.4 3.6 4.4 
150 
3 
Table A-2. Means of the incorporation of H thymidine onto porcine 
peripheral blood lymphocyte cultures, expressed as counts 





































































PI 1833 1831 85396 
28 lation IPRV 1862 1830 89713 
28 MLPRV 2033 2398 90505 
28 6 PI 1980 9554 84165 
28 6 IPRV 3607 24160 85488 
28 6 MLPRV 4218 26785 83375 
14 11 PI 2994 9584 85326 
14 11 IPRV 4817 16328 55442 
14 11 MLPRV 7444 24971 41585 
14 36 PI 4237 16328 120000 
14 36 IPRV 2878 10448 90475 
14 36 MLPRV 5771 15898 144325 
14 60 PI 4751 10680 139745 
14 60 IPRV 8998 19905 113652 
14 60 MLPRV 9478 15286 112171 
151 
3 
Table A-3. Means of the incorporation of H thymidine onto porcine 
peripheral blood lymphocyte cultures of non-exposed swine, 
expressed as counts per minute (average of 6 wells) 
(0 CO •a 
r4 iH (U C rH rH CO 
b (U (U 0) o cd 00 O O O A 
•o (U "H •U «O VO'O S 
Vx a C (U H <U 0) •H 
O CO CO CO CO 4J _ o H O \ iH 
S 4J 
O 
> S S PH U 
3 1 PI 810 778 113237 
3 1 IPRV 1366 1992 164427 
3 1 MLPRV 1159 1678 274076 
3 6 PI 4157 680 354594 
3 6 IPRV 964 1149 119263 
3 6 MLPRV 1075 1453 68541 
3 11 PI 973 1947 85355 
3 11 IPRV 3280 3725 163335 
3 11 MLPRV 1601 2321 63406 
3 36 PI 582 1392 176773 
3 36 IPRV 2082 1945 283359 
3 36 MLPRV 1453 1224 178049 
3 60 PI 5392 1296 122835 
3 60 IPRV 1545 1848 32267 
3 60 MLPRV 939 1274 70779 
Table A-4. Challenge group I 
vaccine n Pre-challenge 6 days AC 11 days AC 
RMPI RMPI RMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 4-2 1564 (1.6) 2514 36400 1972 (1.4) 2815 34450 968 (2.9) 2793 26145 
IPRV 4-2 920 (1.5) 1342 34740 6494 (2.8) 17885 53430 7949 (3.0) 24194 55245 
MLPRV 4-2 1138 (1.5) 1695 29043 9909 (1.4) 13829 45078 16329 (1.1) 17755 34885 
36 days AC 60 days AC 
RMPI 
1640 ratio PRV PHA-P 
RMPI 
1640 ratio PRV PHA-P 
PI 2 5164 (3.6) 18679 128518 2994 (5.9) 17501 166048 
IPRV 2 4385 (2.0) 8548 113664 24998 (1.6) 39965 119331 
MLPRV 2 9084 (3.0) 31202 141970 3877 (4.2) 16378 131006 
Table A-5. Challenge group II 
vaccine n Pre-challenge 6 days AC 11 days AC 
RMPI KMPI RMPI 
1940 ratio PRV PHA-P 1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 4-2 1500 (2.5) 3804 123953 2779 (4.8) 13312 147787 660 (2.0) 1328 83369 
IPRV 4-2 2579 (1.9) 4842 199436 2735 (4.0) 11394 65614 3013 (1.3) 4009 44668 
MLPRV 4-2 2179 (3.0) 6883 141084 3628 (1.1) 3909 83647 1840 (2.7) 5019 174043 
36 days AC 60 days AC 
RMPI 
1640 ratio PRV PHA-P 
RMPI 
1640 ratio PRV PHA-P 
PI 2 1193 (1.7) 2033 97966 3256 (1.2) 3816 326832 
IPRV 2 818 (1.3) 1034 63157 19536 (0.8) 15715 192831 
MLPRV 2 505 (1.9) 945 84559 5602 (1.4) 7838 215461 
Table A-6. Challenge group III 
vaccine n Pre-challenge 
BMPI 
1640 ratio PRV 
PI 4-2 1920 (1.0) 1922 80862 4220 
IPRV 4-2 1031 (1.0) 1043 67394 8654 
MLPRV 4-2 1184 (1.1) 1333 85796 7202 
6 days AC 11 days AC 
BMPI 
PHA-P 1640 ratio PRV PHA-P 
(0.7) 2852 34442 2537 (1.3) 3279 66064 
(2.5) 21702 115213 5854 (2.7) 15787 62435 
(3.0) 23734 56734 23990 (1.1) 25269 55035 
RMPI 
PHA-P 1640 ratio PRV 
36 days AC 60 days AC 
RMPI BMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 2 4050 (2.1) 8400 107122 10355 (1.2) 12213 210718 
IPRV 2 1705 (4.1) 7044 51404 4449 (2.6) 1649 144185 
MLPRV 2 18915 (1.0) 19206 118909 34235 (0.9) 32143 168681 
Table A-7. Challenge group IV 
vaccine n Pre-challenge 6 days AC 11 days AC 
__ ___ __ 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 4-2 2500 (0.3) 826 95905 1728 (1.0) 1743 93375 2132 (2.8) 5923 61325 
IPRV 4-2 3493 (0.4) 1358 110846 2473 (1.9) 8231 128671 2152 (8.6) 18599 164577 
MLPRV 4-2 4439 (0.4) 1858 119751 5235 (5.8) 30305 113375 995 (15.7) 15581 84707 
36 days AC 60 days AC 
RMPI 
1640 ratio PRV PHA-P 
RMPI 
1640 ratio PRV PHA-P 
PI 2 5657 (0.7) 4093 134598 4225 (1.0) 4340 4739 
IPRV 2 580 (3.0) 1703 125678 1997 (2.0) 4611 60731 
MLPRV 2 1675 (3.6) 6044 140744 1208 (11.9) 14337 55356 
Table A-8. Challenge group V 
vaccine n Pre-challenge 
^PÏ 
1640 ratio PRV 
PI 4-2 2084 (0.8) 1601 38450 557 
IPRV 4-2 2674 (0.7) 1841 42862 884 
MIPRV 4-2 1968 (1.2) 2302 59978 432 
6 days AC 11 days AC 
PHA-P 1640 ratio PRV PHA-P 
(1.9) 1079 24471 11677 (1.4) 16593 72320 
(6.3) 5525 38884 4445 (3.0) 13663 87785 
(26.6) 11499 66132 2249 (6.5) 14583 26848 
EMPI 
PHA-P 1640 ratio PRV 
36 days AC 60 days AC 
RMPI RMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 4-2 7169 (7.0) 51516 87524 3403 (2.0) 7012 110613 
IPRV 4-2 5770 (4.0) 23222 69169 830 (2.0) 1626 112024 
MLPRV 4-2 3250 (4.3) 13806 188413 552 (5.0) 2797 105806 
Table A-9. Challenge group VI 
vaccine n Pre-challenge 6 days AC 11 days AC 
EMPI RNPI EMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 4-2 1373 (0.8) 1117 110058 1064 (7.0) 7513 102517 842 (8.4) 7098 80116 
IPRV 4-2 1324 (0.8) 994 101661 1608 (46.1) 74734 128135 1080 (8.2) 8815 55848 
MLPRV 4-2 1564 (1.0) 1517 103401 1012 (70.6) 71448 80543 928 (26.8) 24853 59431 
36 days AC 60 days AC 
RMPI RMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 2 1306 (12.2) 15970 80809 7480 (1.9) 14227 38434 
IPRV 2 1344 (16.8) 22531 87278 7263 (7.4) 53843 105150 
MLPRV 2 1203 (16.2) 19423 136700 16621 (0.9) 14761 53282 
Table A-10. Challenge group VII 
vaccine n day 1 day 6 day 11 
RMPI RMPI RMPI 
1640 ratio PHA-P 1640 ratio PHA-P 1640 ratio PHA—P 
PI 4-2 1890 (0.6) 1031 112146 1539 (24.4) 37566 152113 2140 (14.0) 30124 55272 
IPRV 4-2 1015 (1.4) 1392 71052 2120 (12.1) 25669 79264 9229 (3.2) 29227 55721 
MLPRV 4-2 1763 (0.7) 1197 94486 2112 (15.5) 32973 138067 5789 (12.4) 71739 72440 
day 36 day 60 
RMPI 
1640 ratio PRV PHA-P 
RMPI 
1640 ratio PRV PHA-P 
PI 2 5122 (2.7) 13610 203468 1546 (10.1) 15651 77631 
IPRV 2 5544 (1.6) 9059 122980 3850 (3.1) 11928 61315 
MLPRV 2 5765 (3.6) 20665 198979 4255 (4.4) 18748 55608 
Table A-11. Non-challenge pigs, group VII 
vaccine n day 1 day 6 day 11 
RMPl RMPI RMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 1 633 (1.1) 692 191210 786 (1.3) 1005 186735 1958 (0.6) 1145 419457 
IPRV 1 3471 (0.4) 1534 832980 794 (0.6) 489 123393 4523 (0.6) 2574 72352 
MLPRV 1 3346 (0.8) 2715 296485 480 (1.3) 603 161342 5417 (0.6) 3137 85757 
day 36 day 60 
RMPI RMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 1 1480 (0.5) 750 204961 1623 (0.8) 1214 44324 
IPRV 1 2594 (0.8) 2007 163579 1224 (1.2) 1437 45826 
MLPRV 1 1781 (0.6) 976 240722 3276 (0.7) 2272 39958 
Table A-12. Non-challenge pigs, group V 
vaccine n day 1 day 6 day 11 
RMPI EMPI EMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 1 1224 (1.0) 1259, 51473 837 (2.3) 1882 49783 3376 (0.3) 1029 294217 
IPRV 1 1247 (0.5) 629 59,997 487 (0.9) 450 32994 2423 (0.6) 1464 275396 
MLPRV 1 555 (2.4) 1347 57471 298 (0.8) 244 32386 1135 (0.4) 503 120636 
day 36 
RMPI 
1640 ratio PRV 
PI 1 2357 (0.4) 901 
IPRV 1 722 (1.4) 982 
MLPRV 1 854 (1.7) 1475 
day 60 
RMPI 
PHA-P 1640 ratio PRV PHA-P 
55801 1270 (0.7) 840 232991 
109181 515 (0.8) 395 109400 
361824 418 (0.8) 328 70002 
Table A-13. Non-challenge pigs, group VI 
vaccine n day 1 day 6 day 11 
RMPI EMPI RMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 1 478 (1.0) 479 97029 818 (0.7) 539 146666 505 (1.5) 746 140688 
IPRV 1 638 (0.9) 558 32369 1819 (0.7) 1325 77185 2033 (1.7) 3423 240961 
MLPRV 1 1439 (0.9) 1326 146364 4234 (0.7) 3119 85393 1206 (1.6) 1865 66865 
day 36 day 60 
RMPI RMPI 
1640 ratio PRV PHA-P 1640 ratio PRV PHA-P 
PI 1 333 (1.3) 419 269599 3599 (0.4) 1412 91192 
IPRV 1 2109 (1.5) 3188 323996 421 (1.9) 818 24576 
MLPRV 1 1229 (1.1) 1350 77613 4880 (1.0) 5004 57891 
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Table A-14. Number of pigs that seroconverted at 7 and 60 days after 
challenge. The values in parentheses are the serum 
neutralization titers 
V 4-1 
a. 3 to c « 
CO o 
J-i CO «H 
00 . ,C C 4J W 
•HO n) o td (U C «H O N < N 
60 O 4J < -H 14 
O C e Cd i-J (OHC  0 )  ^ C ( o  t S M  c d m  
• c
•H to (3 (0 Cd (0 
•H M w cd O cd 0) -a O •a 9 4J Cd (U <U •H o 
> M. CO a 4-1 0 vo 
•H I-) " B W C SUM 
O  r 4  ( U U C d  S * J  > 0  S 4 J ( 1 )  
o  c a  a o - o  S s + j  > J 3 4 J  
W) JS "H q) < T4 O (U(U*H 
> C  O w  r~ 1 0 C 4J C (0C4J 
PI 2 I 1 2 (4-4) 2 2 (64-64) 
IPRV 2 I 1 2 (256-64) 2 2 (256-64) 
MLPRV 2 I 1 2 (265-256) 2 2 (256-32) 
PI 2 II 3 0 (<2-<2) 2 0 ( 2- 2) 
IPRV 2 II 3 2 (256-2) 2 0 ( 2- 2) 
MLPRV 2 II 3 2 (4-2) 2 0 ( 2- 2) 
PI 2 III 5 0 (<2-<2) 2 2 (64-128) 
IPRV 2 III 5 2 (64-64) 2 2 (128-128) 
MLPRV 2 III 5 2 (256-16) 2 2 (128-128) 
PI 2 IV 8 0 (<2-<2) 2 2 (128-32) 
IPRV 2 IV 8 2 (32-32) 2 2 (256-34) 
MLPRV 2 IV 8 2 (128-128) 2 2 (64-128) 
PI 2 V 10 0 (<2-<8) 2 2 (16-64) 
IPRV 2 V 10 2 (64-16) 2 2 (32-128) 
MLPRV 2 V 10 2 (8-16) 2 2 (64-128) 
PI 2 VI 12 1 (<2-4) 2 2 (16-16) 
IPRV 2 VI 12 2 (16-32) 2 2 (32-16) 
MLPRV 2 VI 12 2 (4-4) 2 2 (16-16) 
PI 2 VII 14 0 (<8-<8) 2 2 (16-16) 
IPRV 2 VII 14 2 (32-32) 2 2 (64-32) 
MLPRV 2 VII 14 2 (8-32) 2 2 (16-64) 
